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Summary 
The eukaryotic initiation factor 2 (eIF2) is a protein complex which is part of the 
cellular translation machinery. eIF2 comprises three subunits (α, β, γ), the γ 
subunit being the one which contains a GTP-binding domain and binding sites for 
the other two subunits α and β to interact. eIF2 acts in the initial part of the protein 
synthesis, forming a complex with GTP and Met-tRNAMeti. This ternary complex 
associates itself with the 40S subunit of the ribosome and, in a cap-dependent 
manner, scans the mRNA with the help of other factors. The recognition of the 
first AUG codon leads to the final assembly of the ribosome and the translation of 
the protein. Due to eIF2 importance, mutations in highly conserved regions of 
their genes might be lethal; however, a EIF2S3 mutation was recently found to be 
responsible for intellectual disability in male patients. In those patients, signs of 
problems in nervous system development are accompanied by a broad spectrum 
of other symptoms such as obesity, microgenitalism and ataxia gait, a syndrome 
known as MEHMO. This finding has motivated the present study in investigating 
why function disruption in a central player of protein translation mainly impacts on 
nervous system development. Patient-derived iPS cells were generated, and 
served as the model to learn more about eIF2, its impact on the cell proteome 
and its function in early neuronal development. The global translation profile from 
the iPSCs was obtained by SILAC-based LC-MSMS analysis, and the expression 
of candidate genes was assessed in a high-throughput manner at different time 
points of neuronal differentiation. A specific increase in APOE and CRABP1 
(retinoic acid related proteins) translation and transcription was observed in 
patient cells, whereas CBS and TKT protein levels were decreased. Interestingly, 
other genes correlated to translation regulatory mechanisms were also 
differentially expressed. All this data indicates an imbalance of survival/apoptotic 
pathways activation due to translational impairment. Although the present results 
need further confirmation, this alteration on translation rates (iPSCs) suggests a 
very early embryonic development effect of the mutation. The findings on altered 
candidate proteins/mRNAs might open new avenues for future research. This 
hopefully will contribute to the understanding of both, the eIF2S3 roles so far not 
described and the exact functional consequences of the mutation.  
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1. Background 
1.1. Protein synthesis 
1.1.1. Importance of protein synthesis regulation 
Apart from non-coding RNA (e.g. ribosomal RNA, tRNA and miRNA), proteins are 
the ultimate product of gene expression. On the one hand, proteins delineate the 
broadly variable cell shape by forming the membrane, the cytoskeleton and the 
extracellular matrix. On the other hand, they act on intra and extra-cellular 
communication through diverse signaling pathways coordinating countless 
processes, such as biosynthesis, cellular growth, division, differentiation, 
catabolism and apoptosis. Thus, the cellular proteome pattern is constantly being 
adjusted in response to intrinsic and extrinsic signals to maintain homeostasis 
and activate various cellular processes. This continuous control of protein levels 
is accomplished by several regulatory mechanisms that range from epigenetic 
gene silencing to multiple transcription factor networks, thereby regulating gene 
expression. Moreover, protein levels are determined by its degradation rates that, 
in mammals, occurs mainly via ubiquitin and lysosomal-mediated proteolysis. 
A cell proteome is finally governed by controlled transcript translation. Due to the 
importance of protein balance and to the high energy consumption involved in 
protein synthesis, it is logical that mRNA translation is tightly regulated and can 
be aborted, especially in its initial phase to avoid energy misuse. 
Localized translation is a good example of the protein translation regulation 
significance for certain cellular needs. The long distance transport of mRNA in 
highly polarized cells (e.g. neurons) enables a localized, and rapid translation in 
response to distinct stimuli. In this way, on-site translation is able to avoid protein 
degradation during its transport and unintended signaling modulation, since the 
same protein can fulfil different functions in different cellular regions. Besides that, 
the localized protein translation permits a finer spatial control of its concentration. 
Another recent and interesting example of the importance of regulation during 
translation is the finding that protein levels during mitosis are mainly governed by 
changes in translation, rather than changes in transcription (Tanenbaum et al., 
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2015). 
1.1.2. Eukaryotic translation initiation modes 
The first proposed mechanism for eukaryotic translation initiation refers to the 
scanning feature of the ribosome, and to a gain in mRNA ribosomal recognition 
through the 7-methylguanosine bound to mRNA 5´end (5´cap structure) (Kozak, 
1978). This mechanism, later known as cap-dependent initiation (canonical 
initiation), was probably first identified due to its expressive efficiency, when 
compared to other mechanisms so far described. Although the canonical initiation 
mechanism elucidated many issues, such as higher translation rates for mRNA 
presenting cap structures, it could not cover many other concerns that started to 
be unveiled with the development of the field, now provided with mass 
spectrometry and high-throughput sequencing technology, for instance.
The classical view of a mature eukaryotic mRNA having one unique coding 
sequence (CDS), and being therefore monocistronic, has been recently 
challenged (Mouilleron et al., 2016). The substantial number of evidences 
collected by the authors also raises the question whether the usual 100 codons 
cut-off, which classifies an ORF (open reading frame) as CDS, would not exclude 
physiological relevant “short” coding alternative ORFs located upstream and/or 
downstream to the CDS, or even overlapping with it.  
The canonical model for initiation would be incompatible with polycistronic 
eukaryotic mRNAs, as the scanning ribosome would preferentially start at the first 
alternative coding ORF translation over the CDS. Therefore, as a result of the 
diversity of transcripts, which can encode more than one polypeptide, several 
efforts have been made in order to explain this apparent incongruity, and new 
translation initiation mechanisms have been described. 
Leak scanning, for example, clarifies how a second start codon (from CDS) is 
preferred to the first start codon from an upstream open reading frame (uORF). 
In principle, a transcript comprising a weak Kozak sequence context around the 
first uORF start codon allows the ribosome to bypass the first uORF (Kozak, 
2002). 
Another version of translation initiation (also called reinitiation), which likewise 
refers to the presence of uORF, interferes in the efficiency of downstream CDS 
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translation inasmuch as it can hamper new formation of the translation machinery 
following uORF termination. This CDS translation regulation performed by 
reinitiation depends, among other aspects, on uORF length, its position in relation 
to CDS start codon and the availability of activated ternary complexes to reinitiate 
the translation process. Factors such as the particular/specific secondary 
structure of each transcript, might also play important roles for uORF regulation. 
Thus, to define a unique formula for reinitiation in different transcripts is, so far, 
unrealistic (Wethmar, 2014). 
An additional intricate example of a translation mechanism is the one proposed 
for the human core histone 4 (H4) (Martin et al., 2011). Extremely relevant for 
chromatin replication and gene regulatory processes, the eukaryotic canonical 
histone genes are replication dependent, intronless and their transcripts lack 
polyadenylation (Marzluff, 2005). The absence of polyadenylation at the transcript 
3´end and the presence of a short 5`UTR would, in principle, hinder formation of 
the mRNA closed loop, thereby avoiding the described canonical scanning 
mechanism. However, H4 mRNA presents secondary structures which, 
resembling internal ribosome entry sites (IRESs), attracts the ribosome to the 
5´AUG.  
Also part of the translation initiation mechanisms repertoire is the cap-
independent translation. In this process, the very mRNA nucleotide sequence 
itself is determinant for the formation of secondary structures capable of attracting 
the translational machinery, the previously mentioned IRESs.  
Although in both, IRES-mediated and H4 mechanisms, secondary structures 
recruit the ribosome in a cap-independent way, H4 elongation further demands 
binding of eIF4E and the cap-structure (Martin et al., 2011). Additionally, the 
IRES-mediated translation mode, also called internal initiation, does not require 
an eIF4F complex and therefore its efficiency, normally low, is increased in 
conditions where eIF4F is down regulated (e.g. infection, inflammation and other 
processes triggered by stress) (Johannes et al., 1999). It is still worth mentioning 
that this mechanism is focus of much debate, and unlike it happens with viral 
mRNA, the existence of IRES in cellular mRNA is not a consensus (Merrick, 
2004).  
Finally, the diversity in mature mRNA along with the absence of a universal mode 
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for translation initiation illustrates the complexity of the regulatory mechanisms 
coordinating protein synthesis in eukaryotic cells. Although cellular mechanisms 
for regulation of protein synthesis has being studied for decades, many aspects 
of translation in different cell types and physiological states are still to be 
uncovered. 
1.1.3. Canonical eukaryotic translation initiation 
The eukaryotic translation is classically divided into three phases; namely: 
initiation, elongation and termination. Initiation is the phase in which most of the 
factors participate, probably because it is in this stage that protein synthesis can 
be regulated, in an energy saving mode, avoiding unnecessary translation 
initiation and proteolysis. 
The canonical translation initiation is characterized by 43S pre-initiation complex
assembly, in which the 40S ribosomal subunit binds activated eIF2 (GTP-bound) 
carrying methionylated initiator tRNA (Met-tRNAMeti) and several other eukaryotic 
factors (eIF3, eIF1A, eIF1, eIF5) that support both complex stability and start 
codon fidelity (Maag et al., 2006; Nanda et al., 2013; Sokabe and Fraser, 2014). 
In the 1970s, the necessity for assembling ternary complex (eIF2-GTP- Met-
tRNAMeti) and other factors to 40S ribosomal subunit before binding the transcript, 
was already recognized (Safer et al., 1978). Still, in the same study, the authors 
observed that the recruitment of the ribosome to mRNA must be the rate-limiting 
step of translation (Safer et al., 1978), evoking the regulatory role this step should 
have in controlling levels of protein synthesis, as mentioned earlier. 
Following pre-initiation complex formation, its attachment to mRNA 5´-end is 
guided by another set of initiation factors (eIF4F, eIF4B, eIF3 and PABP) that fulfil 
new functions, such as cap-binding, unwinding of mRNA secondary structures, 
and bridging of transcript 5´-end to poly-(A) tail in order to form a “closed loop”. 
PABP is still believed to contribute to ribosome recycling and tethering of eIF4F 
to the cap structure (Jackson et al., 2010). Once the 43S pre-initiation complex is 
bond to the transcript, the Met-tRNAMeti anticodon, present in the peptidyl-tRNA 
binding site of the small ribosomal subunit, is consecutively inspecting the mRNA 
sequence, scanning for the start codon (AUG). AUG recognition triggers GTP 
(eIF2-bond) hydrolysis in a reaction promoted by eIF5. The subsequent 
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displacement of initiation factors succeed and binding of the larger ribosomal 
subunit (60S) takes place to form the 80S functional ribosome machinery (Figure 
1). 
A ribosome harbors the catalytic center, wherein protein synthesis effectively 
occurs. Its structure consists of three t-RNA sites or EPA, abbreviation of: Exit, 
Peptidyl-tRNA binding and Aminoacyl-tRNA binding sites. The A-site 
accommodates the next codon to be paired with the selected charged tRNA 
anticodon. The peptide bond formation occurs between A-site located amino 
group and the ester group placed on P-site. Posteriorly to peptide bond formation, 
the growing peptide chain, before attached on peptidyl-tRNA, moves to the A-site 
tRNA and the ribosome translocates. Thereby, discharged t-RNA moves to the E-
site, from where it exits the ribosome. 
The amino acid polymerization, or elongation phase, described above proceeds 
towards the 3´end of the transcript. Translation termination is marked by stop 
codon (UAA, UAG, and UGA) recognition, when release factors bind to the 
ribosomal A-site, releasing the new synthetized protein and disassembling the 
ribosome subunits. Dever and Green, 2012 provide a detailed discussion about 
elongation and termination mechanisms, as well as about involved factors and 
recycling aspects of translation (Dever and Green, 2012). 
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Figure 1. Canonical Eukaryotic Translation Initiation. Simplified scheme of the canonical 
eukaryotic translation initiation steps: Translation is initiated by activation of eIF2 (GTP-
bound). The formation of the ternary complex is completed by binding of Met-tRNAMeti, which 
is then able to bind to 40S ribosome subunit together with eIF1, eIF1A, eIF3 and eIF5 to form 
the 43S pre-initiation complex. Attachment of the 43S complex to the transcript is 
accomplished as a result of binding of the eIF4 complex, eIF4B, eIF3 and PABP. Thus, the 
formed complex is able to scan for the start codon, and the latter recognition triggers binding 
of 60S ribosome subunit, thereby constituting an elongation competent machinery. 
1.1.4. eIF2 heterotrimeric complex 
Purified over 40 years ago, eIF2 was identified together with Met-tRNAMeti and 
GTP as being part of a pre-initiation complex, later termed ternary complex 
(Gupta et al., 1973; Levin et al., 1973), and over all those years various aspects 
of eIF2, such as partners interactions, activity regulation and targeted pathways 
have been deeply investigated.  
Consisting of three distinct subunits; i.e., eIF2S1 (eIF2α), eIF2S2 (eIF2β) and 
eIF2S3 (eIF2γ), the eukaryotic initiation factor 2 has been conserved throughout 
evolution, fact that supports its relevance in translation. Furthermore, presence 
of eIF2S1 and eIF2S2 subunits has been shown to be essential for life, while 
particular mutations on eIF2S3 generate infertile mice and a mental retardation 
syndrome in humans (Borck et al., 2012; Heaney et al., 2009; Matsubara et al., 
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2015; Scheuner et al., 2001). It is noteworthy to mention that mice carry two 
eIF2S3 homologues and that the X homologue can apparently compensate for 
the absence of Y chromosome encoded eIF2S3, by generating fertile mice 
(Yamauchi et al., 2016). Thus, if a more aberrant phenotype, such as embryonic 
lethality and neuronal impairment, was not observed in mice (Matsubara et al., 
2015), does not necessarily mean that a complete deletion (of both X and Y gene 
homologues) or a double mutation would not cause severe consequences. 
The solved crystallographic structure of an eIF2 homologous factor, the archaeal 
aIF2 complex (Stolboushkina et al., 2008; Yatime et al., 2007) revealed for its 
subunit 3 a structure-function relation which elucidates previous findings of 
biochemical assays. Considered to be the complex core, subunit 3 of aIF2 
interacts with the other two subunits, which do not seem to bind themselves 
(Schmitt et al., 2002; Yatime et al., 2006). Nevertheless, human eukaryotic 
binding assays (Rajesh et al., 2008; Suragani et al., 2005) show that all the three 
subunits interact with each other, revealing a more complex regulatory network 
for human factors in comparison to its orthologue. 
Playing a central role in the canonical translation initiation, eIF2 subunits possess 
interesting features which confer them the ability to both promote and restrict 
canonical translation initiation, depending on environmental conditions. eIF2S3 is 
a guanine nucleotide binding protein, cycling from inactive (GDP-bound) to active 
(GTP-bound) states. In its active state, eIF2 is able to anchor Met-tRNAMeti, 
forming this way the ternary complex (Figure 2) (Kapp and Lorsch, 2004). This 
activation is therefore expected to be regulated, due to its consequential role in 
protein synthesis control.  
The GDP-GTP switch is catalyzed by another translation factor, named eIF2B, 
and the control of this catalysis is done by a group of eIF2S1 kinases. The 
mammalian kinases HRI, PKR, PERK, and GCN2 are able to phosphorylate 
Ser51 residue of eIF2S1 in response to heme deficiency, viral infections, ER 
stress and amino acid deprivation, respectively (Donnelly et al., 2013). This 
phosphorylation produces a significant increase in affinity between the eIF2S1 
and the eIF2B regulatory subcomplex (α, β and δ subunits). The phosphorylated 
eIF2S1 Ser51 (phospho-eIF2S1) acts as a competitive inhibitor for eIF2B, 
impairing the latter guanine nucleotide exchange factor role, thereby precluding 
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protein synthesis (Figure 2) (Krishnamoorthy et al., 2001; Nika et al., 2001).  
 
 
Figure 2. Ternary complex formation. eIF2 activation switches from GDP to GTP binding 
mode, by the action of a GTP exchange factor (eIF2B). Upon start codon recognition, GTP 
hydrolysis takes place via eIF5, deactivating and recycling eIF2. Regulation of eIF2-GTP 
levels is accomplished by eIF2S1 phosphorylation, which in this form, has a higher affinity to 
eIF2B, hampering its GTP exchange role.  
For the purpose of investigating additional eIF2 post-translational modification 
sites, aside from eIF2S1 Ser51, that could act as regulatory sites, a recent mass 
spectrometry study evaluated the three eIF2 subunits and encountered highly 
phosphorylated N-terminal in eIF2S2 (Beilsten-Edmands et al., 2015). This post- 
translational modification could be the key to explain a regulation in the GTP 
hydrolysis process, since eIF2S2 is interacting with GTP, as well as with eIF5 
(GTPase-activating factor) and eIF2B (GTP exchange factor) (Asano et al., 1999; 
Chakrabarti and Maitra, 1992; Kimball et al., 1998). 
Besides presenting a binding interface with GTP, eIF2S2 also plays a role in 
mRNA and Met-tRNAMeti binding. However, the G-protein eIF2S3 is considered 
the major binding site for Met-tRNAMeti (Bommer and Kurzchalia, 1989; Flynn et 
al., 1994; Gaspar et al., 1994; Gonsky et al., 1992; Laurino et al., 1999; Naveau 
et al., 2013; Nika et al., 2001; Roll-Mecak et al., 2004; Schmitt et al., 2010). 
A point mutation in the backside of the eIF2S3 GTP-binding domain was the first 
EIF2S3 human described mutation (Borck et al., 2012). The iPS patient cells 
developed in the present study originate from a somatic cell line presenting a 
frameshift mutation, predicted to cause a truncation at the C-terminus of eIF2S3. 
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While archaeal eIF2S3 N-terminus (G domain) together with domain II are known 
to be required for Met-tRNAMeti binding, mutation on domain III (C-terminal) 
impairs binding to ribosomal 40S (Roll-Mecak et al., 2004; Shin et al., 2011). 
To conclude, being eIF2S3 central for translation in all cell types, the gene 
mutations broad phenotype is intriguing. Therefore, we believe the human 
EIF2S3 mutation iPSC line to definitely provide an invaluable model to unveil 
pathophysiological aspects of this translation machinery element. 
1.2. Embryonic neuronal development and disease 
1.2.1. Neuronal differentiation during embryogenesis 
Subsequent to fertilization, a series of cellular divisions give rise to the blastocyst, 
a structure characterized by its polarized arrangement and its two different cell 
populations, an outer cell mass or trophoblast, and an inner cell mass composed 
by two lineages; i.e. epiblast and primitive endoderm (or hypoblast). Both 
trophoblast and hypoblast are responsible for the formation of extra-embryonic 
structures, whereas the epiblast is mainly committed to embryonic development 
itself.  
Following embryonic implantation into the endometrium, cells reorder to form the 
primitive streak. This cellular reorganization marks a critical event, the 
gastrulation, which converts the epiblast into three embryonic germ layers 
(endoderm, mesoderm and ectoderm). 
The ectoderm is the layer originating all structures of the nervous system (central 
and peripheral). Considered to initiate even earlier in development (sixteen- 
blastomere stage) (Gaur et al., 2016; Streit et al., 2000), the neural specification 
is just observed on the third gestational week, when ectoderm underlying 
structures (notochord and mesoderm) release morphogens that contribute to the 
neural plate emergence within the ectoderm. The neural plate invaginates 
producing neural folds, which in turn fuse into a neural tube. This tubular structure 
is ultimately responsible for the formation of the brain, spinal cord and posterior 
pituitary gland. The surface ectoderm (external ectoderm), which merges again 
after detachment of the neural tube, is deriving among other structures skin and 
the anterior pituitary gland. 
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The lateral edges of the neural plate form the so called neural crest, which 
differentiates from the neural tube and overlying ectoderm by its capacity of 
migration to populate diverse tissues, such as autonomic ganglia that innervates 
many organs. Thus, the neural crest is the origin of the peripheral nervous 
system. Finally, the neural tube lumen give rise to the adult ventricular system. 
Ventricles walls are lined by ependymal cells and in distinct locations by choroid 
plexus, major responsible for cerebrospinal fluid (CSF) production, and that 
constitute part of the blood-brain barrier. Furthermore, ventricles walls 
accommodate a population of neural stem cells and therefore the subventricular 
zone is recognized as the bulk of adult neurogenesis (Fuentealba et al., 2012). 
During the fourth developmental week, the neural tube folds to form the primary 
brain vesicles; namely: prosencephalon (forebrain), mesencephalon (midbrain) 
and rhombencephalon (hindbrain), which will in addition to the spinal cord form 
the adult central nervous system.  
As exposed here, the sequential events that determine vertebrate development 
are highly complex, and governed by multiple signaling pathways. Several 
patterning molecules that have been focus of extensive studies, are known to act 
during the very early neuronal commitment. WNT (Bielen and Houart, 2014), 
NOTCH (Louvi and Artavanis-Tsakonas, 2006), BMP (Liu and Niswander, 2005) 
and SHH (Fuccillo et al., 2006; Komada, 2012) are examples of crucial regulators, 
controlling cellular self-renewal, proliferation and fate determination.  
In addition to influence in embryonic development rate, retinoic acid levels has an 
impact on the formation of fore-, mid- and hindbrain (Okada et al., 2004) and level 
variations can even be the cause of death in post-implantation embryos (Huang 
et al., 2005; Niederreither et al., 1999). Retinoic acid is another essential molecule 
that presents a broad range of actions, modulating diverse gene expression in 
combination with co-factors. Lack or loss of function of proteins related to retinoic 
acid homeostasis resulted in a wide variety of neurological disorders (Rhinn and 
Dolle, 2012). 
1.2.2. Neurodevelopmental disorders and translation  
The maintenance of approximately 86 billion healthy and functional neurons, and 
the same number of healthy and functional glial cells (Azevedo et al., 2009) is 
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energetically very costly for humans. Keeping both ionic balance and 
neurotransmitters homeostasis is essential and enables a neuron to fire and send 
diverse signals into its network of synapses. Processes such as; 
neurotransmitters synthesis, uptake, and catabolism, in addition to ionic traffic 
across membranes are essentially costing considerable amount of energy (Du et 
al., 2008). Therefore, the energy consumed by the brain is mainly used to re-
establish ionic gradients. The protein synthesis, which is generally considered to 
be a major energy-demanding cellular process, does not have a great effect on 
brain energy consumption (Engl and Attwell, 2015).  
Although translation is not among the highly energy costing process in the brain, 
its control has been identified as an important mechanism regulating neuronal 
plasticity (Zukin et al., 2009), and its disruption has been associated to various 
neurodevelopment and neurodegenerative disorders (Jung et al., 2014). The 
impact that protein levels can have on the nervous system is possibly mediated 
due to the rapid molecular response required for synaptic signaling changes. 
Supporting this idea, axonal and dendritic local protein synthesis has been 
described (Jung et al., 2012; Sutton and Schuman, 2005) along with mechanisms 
of translational activation by neuronal stimuli triggering microRNA degradation 
(Fu et al., 2016). This demonstrates the importance to maintain dynamic 
regulation of protein levels in neuronal compartments. Despite of being essential 
for all tissues, it is not unwise to assume that proteome regulation in the brain is 
far more refined, and responsive to environmental changes, exhibiting therefore, 
a much faster phenotypic change in comparison to other organs. Corroborating 
with this, mutations known to affect the translational machinery have been 
associated to both neurodevelopmental and neurodegenerative disorders. The 
molecular mechanisms underlying these pathologies are focus of recent interest 
but are still poorly understood.  
Neurodegenerative disorders, as Alzheimer, Parkinson, and autism spectrum 
disorder (ASD) are linked to a global decrease of translation via phosphorylation 
of eIF2S1 (Jung et al., 2014). Neurodevelopmental syndromes, such as Fragile 
X (FXS), Prader-Willi (PWS), Angelman (AS), Vanishing White Matter (VWM), 
besides the newly described PPP1R15B and MEHMO, have being assigned as 
consequences of mutation in genes directly related to translation. 
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Figure 3. MEHMO and other syndromes affecting translation initiation.  
The guanine nucleotide exchange factor eIF2B is a key translation regulatory 
protein, and it is normally present in much lower levels when compared with eIF2, 
therefore a small fluctuation on levels of active eIF2B can substantially affect the 
amount of active eIF2-GTP and thus global translation initiation (Singh et al., 
2007). As described before, an effective inhibition of eIF2B is done by the 
phosphorylated form of eIF2S1 that is in higher concentrations in the absence of 
PPP1R15B. PPP1R15B is known to be an eIF2S1 phosphorylation repressor due 
to its role of recruiting a phosphatase to eIF2S1. A missense mutation on this 
gene is causing a series of symptoms which highly remember MEHMO syndrome 
(Abdulkarim et al., 2015; Harding et al., 2009; Kernohan et al., 2015).  
PPP1R15B mutation is not the only causing eIF2S1 phosphorylation imbalance. 
Although mice lacking eIF2S1 kinases GCN2 or PKR, or expressing a non-
phosphorylatable form of eIF2S1 have altered synaptic plasticity and memory 
(Costa-Mattioli et al., 2005; Costa-Mattioli et al., 2007; Zhu et al., 2011), the 
consequent decrease of phospho-eIF2S1 is mainly associated with early-onset 
of diabetes and obesity or death per hypoglycemia. This contradicting glycemic 
effects (either hypo or hyperglycemia) seem to be highly dependent on phospho-
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eIF2S1 availability (Harding et al., 2001; Julier and Nicolino, 2010; Scheuner et 
al., 2001; Scheuner et al., 2005). On the other hand, and in line with the features 
presented by PPP1R15B mutation, lack of a PACT/RAX (causing increase in 
phospho-eIF2S1) leads to anterior pituitary hypoplasia and growth restriction, 
MEHMO syndrome symptoms. It is interesting to note that anterior pituitary cells 
are expressing high levels of RAX, indicating a possible relevance on the control 
of phosphorylated eIF2S1 levels in this tissue (Dickerman et al., 2015). 
Similarly to what is observed in proteins regulating phospho-eIF2S1 levels, 
mutation in any of the eIF2B subunits genes is also affecting global translation 
rates causing the so-called Vanishing White Matter disease (Leegwater et al., 
2001; Pavitt and Proud, 2009). Characterized by myelin loss and cerebellar 
ataxia, this disease affects mainly astrocytes and oligodendrocytes, but its 
molecular basis is still unknown. Interestingly, the disease is not considered 
developmental, but to have a progressive nature, as its onset can be precipitated 
by major stress episodes, also in adulthood. Thus, it has been proposed that 
symptoms emergence it is not due to a continuous and preponderant decrease 
of global translation rates, but due to a cellular response to stress, by increasing 
certain mRNA translation, such as e.g. ATF4 (Kantor et al., 2005). However, might 
be important to notice that in the early-onset of the disease, two common features 
in global translation impairment disorders are observed, microcephaly and growth 
failure (Figure 3) (Bugiani et al., 2010). 
Among the neurodevelopmental diseases disturbing translation, particular 
intellectual disability (ID) disorders, namely: Fragile X (FXS), Prader-Willi (PWS), 
Angelman (AS) have been intensively studied and, although they had their 
molecular determinants scrutinized, a lot is still to be unveiled. The basis of these 
syndromes is the ability of their affected proteins to mediate translational control 
by binding target mRNAs (Ashley et al., 1993; Napoli et al., 2008; Schenck et al., 
2001). This regulation takes place mainly on neuronal tissue, a site where these 
syndrome-causing genes are normally highly expressed (Hinds et al., 1993; 
Pathania et al., 2014). 
FXS patients exhibit ID and other neurological symptoms, such as seizures and 
behavioral disorders, besides growth problems and macroorchidism. The disease 
genetic background is commonly the silencing of the FMR1 gene, caused by 
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hypermethylation of an inherited 5´UTR repeat expansion (CGG). FMRP (FMR1-
encoded protein) is participating in neuronal translational control by different 
means, impairing both initiation and elongation phases of protein synthesis. The 
first two involved pathways are related to the inhibition of eIF4E- mRNA binding, 
via FMRP-CYFIP1 interaction (Napoli et al., 2008; Schenck et al., 2001). As 
previously described, along with other factors, eIF4E forms a eIF4F complex to 
bind the 5´cap structure of the mRNA and to attract the 40S ribosomal subunit to 
it. For proper binding to occur, eIF4E needs to be phosphorylated by mitogen-
activated protein kinase (MAPK)-interacting kinase (MNK). Besides MNK, 
activation of the MTORC pathway is also increasing translation rates, through 
eIF4E binding proteins (4E-BP) phosphorylation that, in this form, are not able to 
immobilize eIF4E, thereby allowing cap-dependent translation. Synaptic activity, 
via either BDNF or mGluR stimulation activates the above-mentioned pathways 
and regulates specific mRNA translation (FMRP targets) by induction of CYFP1-
eIF4E dissociation, thus promoting FMRP target mRNA translation (Figure 4). 
The third mechanism, by which translation is regulated is the FMRP interaction 
with the mRNA coding region, blocking ribosome transit and consequently stalling 
elongation. (Bhakar et al., 2012; Richter et al., 2015). 
 
 
Figure 4. Neuronal control of FMRP target mRNAs translation. Simplified scheme 
showing CYFIP1 binding to eIF4E and impairing translation of FMRP target mRNAs. CYFIP1 
affinity to eIF4E diminishes upon eIF4E phosphorylation via BDNF and mGluR stimulation 
and results in eIF4E binding to eIF4G and eIF4A to form the cap-mRNA binding complex 
(eIF4F). The consequent release of CYFIP1 enables translation activation of FMRP target 
mRNAs (Based on (Bassell and Warren, 2008; Bhakar et al., 2012; Napoli et al., 2008)). 
PWS and AS are neurodevelopment disorders characterized mainly by ID. These 
syndromes are caused by deletion of a region on chromosome 15 (15q11-q13), 
which when of paternal origin leads to PWS, and when from maternal 
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chromosome leads to AS. The CYFIP1 gene is located in the previously 
mentioned region and its absence, in both syndromes, is related to a more severe 
form of ID (Bittel et al., 2006; Chung et al., 2015). 
Besides coupling of CYFIP1 and FMRP to control translation by the principle 
exposed before, CYFIP1 is very important for actin cytoskeleton arrangements, 
for it is also a member of the WAVE complex (Bogdan et al., 2004; Kunda et al., 
2003). Coordinating spine morphology changes, BDNF signaling was found to 
shift CYFIP1 from the translation inhibitory complex to the WAVE complex, 
repressing actin polymerization. Therefore mature spine formation depends on 
BDNF signaling combining translation and actin remodeling roles via CYFIP1 
(Chen et al., 2010; De Rubeis et al., 2013). 
Much similar to what is seen in MEHMO, besides ID, PWS is featured by 
hypogonadism, obesity and hypotonia, while epilepsy and absence of speech 
characterize mainly AS. 
Augmenting the list of essential components for proper translation, there are 
some other ribosome-related proteins that have a major impact on brain 
development. For instance, mutations on EIF4A3 (Favaro et al., 2014), RPL10 
(Brooks et al., 2014), EMG1 (Armistead et al., 2015) and PHF6 (Todd et al., 2016; 
Wang et al., 2013a) greatly affect neurodevelopment, causing syndromic ID and 
developmental disorders.  
Finally, delving into the sophisticated embryonic and neuronal translation 
pathways will certainly reveal the overlapping pathogenic mechanisms underlying 
the diseases considered here, and will provide a comprehensive view on the role 
of eIF2S3 in the intricate controlling mechanisms governing physiological 
translation on brain development, and in the disturbed pathways during disease. 
1.2.3.  MEHMO syndrome and eIF2S3  
MEHMO is the acronym formed from the syndrome characteristics; namely, 
Mental retardation, Epileptic seizures, Hypogenitalism, Microcephaly and 
Obesity. This disorder was first clinically described in late 1980s (DeLozier-
Blanchet et al., 1999; Delozier-Blanchet et al., 1989) and it had its genetic 
background partially identified a decade later, when Steinmüller and colleagues 
assigned the disease locus to the short arm of the X-chromosome and proposed 
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a recessive inheritance based on pedigrees of affected families (Steinmuller et 
al., 1998). 
Besides the frameshift mutation that leads to a C-terminus truncation of eIF2S3 
in the patient considered here, a large scale X-chromosome exome sequencing 
considering 208 families presenting X-linked intellectual disability was realized. 
From those 208 evaluated families, 9 showed EIF2S3 point mutations (p.V151L 
and p.K125R) (Tarpey et al., 2009). Another family was reported by Borck and 
colleagues (Borck et al., 2012) to present an EIF2S3 mutation in its pedigree 
genealogical tree. This was the first investigation that raised the possibility that 
the EIF2S3 mutation was actually the genetic cause of MEHMO syndrome. The 
authors concluded that the specific single nucleotide mutation (p.I222T) on the 
GTP binding site of eIF2S3 was ultimately affecting the start codon fidelity on 
yeast studies.  
The same study still (Borck et al., 2012) points out the symptomatic variability 
found in patients having the very same mutation, and expose the difficulty in 
concluding whether MEHMO-associated manifestations constitute reduced 
penetrance or variable expressivity, since even a hallmark symptom, such as 
epilepsy, seems to present significant variance in severity (DeLozier-Blanchet et 
al., 1999). Contrarily, movement disorders, facial dysmorphisms and growth 
retardation are features present in all MEHMO reported cases (Table 1). It is also 
necessary to emphasize that more profound biochemical and anatomical analysis 
of the first patients described were not possible. Brain magnetic resonance 
imaging of the most recent patients could show calcifications in choroid plexus, 
thin corpus callosum and enlargement of lateral ventricles and subarachnoid 
frontotemporal space, characterizing a developmental problem during ventricular 
system formation. The ventricles cavities form, together with the spinal cord canal 
and the subarachnoid space, a communicating network area wherein CSF 
circulates (Lun et al., 2015). Choroid plexus and corpus callosum are structures 
that could be easily compromised by abnormal development of the ventricular 
system (Del Re et al., 2015; Lowery and Sive, 2009; Lyoo et al., 1996)  
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Table 1 Collection of all MEHMO patient features from the different publications. 
Reference Symptoms 
(DeLozier-Blanchet et al., 
1999; Delozier-Blanchet et 
al., 1989) 
 
 Movement disorder- Hypertonia  
 Facial dysmorphisms 
 Growth retardation 
 Hyperglycemia 
 Behavior impairment  
 Speech impairment 
 
 
(Steinmuller et al., 1998) 
 Movement disorder  
 Facial dysmorphisms 
 Growth retardation 
 Diabetes diagnosed at age 6 months 
 Increased levels of fatty acids 
 Fatty liver 
 Small thyroid 
 
 
 
(Borck et al., 2012) 
 Movement disorder - Ataxia gait 
 Facial dysmorphisms  
 Growth retardation 
 Low GH levels 
 Behavioral impairment 
 Speech impairment  
 Enlarged lateral ventricles 
 Thin corpus callosum 
(Stanik, J., Skopkova, M., 
Stanikova, D., Brennerova, 
K., Ukropec, J., Danis, D., 
Kurdiova, T., Ukropcova, B., 
Ticha, T., Klimes, I., 
Gasperikova, D. (2015). 
Genotype and phenotype 
characterization in two 
patients with MEHMO 
syndrome. Abstract 
published in Hormone 
Research in Paediatrics 82, 
Supplement 1) 
 Movement disorder – Hypotonia 
 Facial dysmorphisms 
 Panhypopituitarism (low levels of GH, TSH, ACTH) 
 Diabetes (hypoglycemia in the first 6 months of life) 
 Elevated hepatic enzymes 
 Severe combined dyslipidemia 
 Lactose intolerance 
 Enlarged subarachnoid space; calcifications in 
choroid plexus  
 Myelination delay  
 VCC-atrial septal defect 
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1.3. iPSCs as a neurological disease model system 
Human induced pluripotent stem cells (hiPSCs) are reprogrammed somatic cells 
which acquire the pluripotency characteristics comparable to cells of the 
embryonic inner cell mass, the human embryonic stem cells- hESCs.  
Pluripotency, or cell capacity of generating all three germ layers and self-renew, 
can be assessed by the most stringent test, the tetraploid complementary assay, 
which was shown to be positive also for artificially reprogrammed cells (Zhao et 
al., 2009).  
Being embryogenesis undoubtedly a very delicate ethical issue, much of the 
current knowledge available is derived from mice and other vertebrate models. 
Thus, detailed signaling pathways imperative during embryogenesis and their 
peculiarities in human development are still poorly understood. 
As the hiPSCs transcriptome resembles that of morula blastomeres and epiblast 
cells of the embryo, the limitation to study human neuronal systems can now be 
overcome by the generation of hiPSCs and their differentiation into several 
neuronal types. This turns the hiPSC model into a powerful and attractive tool to 
explore human particularities, which could not be assessed otherwise. 
On the other hand, human developmental processes are challenging to model 
and iPSCs also present their disadvantages, such as differences in epigenetics 
which produces a background that could interfere in a particular gene expression. 
In an attempt to compare gene expression profiles from in vitro and in vivo 
pluripotent cells, Yan and colleagues (Yan et al., 2013) applied single-cell RNA 
sequencing to both human epiblast cells and in vitro hESCs. The analysis showed 
substantial differences in cells´ transcriptomes. However, it is important to 
consider that there are differences in gene expression even among hESC lines 
(Abeyta et al., 2004). The gene expression contrast observed between hESC 
lines is equally found among hiPSCs lines, and also when comparing hiPSCs with 
hESCs. This variance, though, could be explained by the aforementioned diverse 
epigenetic influences but also by non-standardized culture conditions, and non-
standardized protocols among laboratories worldwide - reviewed by (Sullivan et 
al., 2010) -. In addition, a standardized global genome study showed no 
significant differences between lines derived from different sources (Galan et al., 
2013). 
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Thus, although the field of embryogenesis has a lot to profit from stem cells, 
caution has to be taken when designing and evaluating the experiments. The 
expansion of techniques using iPSCs will definitely contribute to better 
understand the complexity involving the interactions of eIF2S3 in pathways of 
translation regulation, and accordingly, affecting transcriptional and post-
transcriptional cellular mechanisms. The latter being explained by the likely ER 
stress, caused by an accumulation of unfolded proteins derived from a 
deregulated translational process. 
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2. Aim 
To have a more comprehensive view about gene expression and translational 
pattern in patients with mutation in EIF2S3 gene, patient-derived iPS cells were 
generated. iPS cells served as a model in the identification of candidate 
genes/proteins which are regulated or affected by eIF2S3. Patients with such a 
mutation present mainly neurological abnormalities. To understand how the 
neuronal activity is impaired in the affected individuals, different stages of 
neuronal differentiation were analyzed via expression of neuronal markers, 
together with genes of interest, which were selected in the course of the study. 
All the data generated here will hopefully give us hints to better assess the role 
of eIF2S3 in brain development. 
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3. Material and Methods 
3.1.  Chemicals, enzymes and commercially available kits 
For the preparation of culture media and all other solutions and buffers, chemicals 
from Merck (Darmstadt, Germany), Sigma-Aldrich® (Darmstadt, Germany) and 
Carl Roth® (Karlsruhe, Germany) were used, when not otherwise indicated. All 
enzymes and corresponding buffers needed were provided by Thermo Fisher 
Scientific™ (Waltham, USA). mRNA extraction and qRT-PCR were performed 
employing QIAGEN (Hilden, Germany) kits (RNeasy Mini® kit; QuantiTect® primer 
assays; QuantiFast® SYBR® Green RT-PCR kit). Plasmid DNA was extracted by 
using JetQuick Gel extraction, PCR purification and Plasmid Miniprep Spin kits 
(GENOMED GmbH - Löhne, Germany) or NucleoBond® Xtra Maxi EF (Macherey-
Nagel - Düren, Germany), for larger amounts of plasmid DNA. 
3.2. Plasmids, primers and antibodies  
All plasmids used for cloning, transfection and viruses production (Table 2) as 
well as the oligonucleotides used for cloning and sequencing (Table 3) are 
grouped below. Table 4 contains a list of all QuantiTect® primers (QIAGEN) used 
during quantitative RT-PCR. Immunostaining and western blot required the 
primary and secondary antibodies listed in Table 5.  
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Table 2. Plasmid constructs used in this study. 
Plasmid Description Source 
eIF2 
pC4291 pcDNA4/TO/myc-His A (EcoRI-XhoI)+EIF2S3 (Borck et al., 2012) 
Kindly provided by Dr. 
Thomas Dever, NIH 
pC4292 Derived from pC4291 (I222T mutation on 
EIF2S3) 
(Borck et al., 2012) 
Kindly provided by Dr. 
Thomas Dever, NIH  
Competent strain and Lentiviral plasmids 
Electrocompetent 
E. coli 
DH5α derivative (Hanahan, 1983) 
pLVX-Tet3G NeoR; Lenti-X™ Tet-On® 3G Inducible 
Expression System 
Clontech 
Laboratories, Inc  
pLVX-TRE3G PuroR; Lenti-X™ Tet-On® 3G Inducible 
Expression System 
Clontech 
Laboratories, Inc 
pLVX-TRE3G-
4291 
Derived from pLVX-TRE3G and pC4291 This study 
pLVX-TRE3G-
4292 
Derived from pLVX-TRE3G and pC4292 This study 
Codon-optimized 
OKSM red 
Multicistronic reprogramming vector (Warlich et al., 2011) 
pSPAX2 GAG/Pol-Vector (lentiviral packaging plasmid) 
Plasmid #12260  
Addgene (Cambridge 
- USA) 
pMD2.G VSVg-Vector (envelope expressing plasmid) 
Plasmid #12259 
Addgene 
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Table 3. Oligonucleotides used in this study 
Primer Sequence (5´→ 3´) Tmelting 
(°C) 
Use 
D_Not_I_fw ATAGCGGCCGCCGTTTAAA
CTTAA 
61 Amplification of 1509bp EIF2S3 WT
gene from pc4291 
D_NdeI_rev CGCCATATGATGAGTTTTTG
TTCGA 
59 Amplification of 1509bp EIF2S3 WT
gene from pc4291 
S3 2f ATGTAGCTCATGGGAAATC
CAC 
52 Identification of EIF2S3 
S3 3f TGTTGACTGTCCTGGCCA 50 Identification of EIF2S3 
S3 4f GCAGAGGGAGCTCCCATTA
T 
52 Identification of EIF2S3 
S3 6f AGGTGTACGCACTGAAGGA
GA 
51 Identification of EIF2S3 
S3 1 rev ATAACTTCGTGTGAAAGTG
GCG 
54 Identification of EIF2S3 
S3 2 rev TGGATTTCCCATGAGCTAC
AT 
51 Identification of EIF2S3 
 
Table 4. Human QuantiTect® primers (QIAGEN) used in this study. 
Primer  
(Gene symbol) 
Gene full name 
ACHE Acetylcholinesterase (Yt blood group) 
AFP Alpha-Fetoprotein 
APOE Apolipoprotein E. 
ATF4 Activating Transcription Factor 4 
ATF5 Activating transcription factor 5 
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Primer  
(Gene symbol) 
Gene full name 
BCL2 B-Cell CLL/Lymphoma 2 
CAMKII (CAMK2G) Calcium/calmodulin-dependent protein kinase II gamma 
CBS Cystathionine beta-synthase 
CHAT Choline O-acetyltransferase 
CRABP1 Cellular retinoic acid-binding protein 1 
CRABP2 Cellular retinoic acid-binding protein 2 
CYFIP1 Cytoplasmic FMR1 interacting protein 1 
CYP26A1 Cytochrome P450, family 26, subfamily A, polypeptide 1 
DDIT3 (CHOP) DNA Damage Inducible Transcript 3 
DLX2 Distal-Less Homeobox 2 
EIF1 (EIF1A) Eukaryotic translation initiation factor 1 
EIF2S1 Eukaryotic initiation factor 2 S1 
EIF2S2 Eukaryotic initiation factor 2 S2 
EIF2S3 Eukaryotic initiation factor 2 S3 
EIF2B1 Eukaryotic translation initiation factor 2B, subunit 1  
EIF2B2 Eukaryotic translation initiation factor 2B, subunit 2  
EIF2B3 Eukaryotic translation initiation factor 2B, subunit 3  
EIF2B4 Eukaryotic translation initiation factor 2B, subunit 4 
EIF2B5 Eukaryotic translation initiation factor 2B, subunit 5 
EIF3A Eukaryotic translation initiation factor 3, subunit A 
EIF3B Eukaryotic translation initiation factor 3, subunit B 
EIF3C Eukaryotic translation initiation factor 3, subunit C 
EIF4A2 Eukaryotic translation initiation factor 4A2 
EIF4E Eukaryotic translation initiation factor 4E 
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Primer  
(Gene symbol) 
Gene full name 
EIF4G1 Eukaryotic translation initiation factor 4 gamma 
EIF5 Eukaryotic translation initiation factor 5  
EOMES (TBR2) T-box brain 2 
EMX1 Empty spiracles homeobox 1 
FMR1 Fragile X mental retardation 1 
FABP4 Fatty acid binding protein 4 
FABP5 Fatty acid-binding protein, epidermal 
FOXA2 Forkhead-Box-Protein A2 
FOXJ3 Forkhead transcription factor 
G6PD Glucose-6-Phosphate Dehydrogenase 
GABBR1 Gamma-aminobutyric acid (GABA) B receptor, 1 
GABRA1 Gamma-aminobutyric acid (GABA) A receptor, alpha 1 
GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase 
GRM1 (MGLUR1) Glutamate Receptor, Metabotropic 1 
GRM5 (MGLUR5) Glutamate Receptor, Metabotropic 5 
GSK3B Glycogen synthase kinase-3 
H2AFX H2A Histone Family Member X 
HMBS Hydroxymethylbilane synthase 
HOMER1 Homer1 
HOXA2 Homeobox A2 
HOXC4 Homeobox C4 
HOXC8 Homeobox C8 
KRT1 Keratin 1, Type II 
KRT18 Keratin, type I cytoskeletal 18 
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Primer  
(Gene symbol) 
Gene full name 
LRAT Lecithin retinol acyltransferase 
LRP8 (APOER2) Low Density Lipoprotein Receptor-Related Protein 8 
(Apolipoprotein E Receptor) 
MAP2 Microtubule-associated protein 2 
MTOR Mechanistic Target Of Rapamycin (Serine/Threonine Kinase) 
MYH6 Myosin, Heavy Chain 6, Cardiac Muscle, alpha 
NANOG Nanog 
NES Nestin 
NRXN1 Neurexin-1-alpha  
NR1H3 (LXRA) Nuclear receptor subfamily 1 group H member 3 
OCT4A Octamer binding transcription factor 4 
OTX2 Orthodenticle Homeobox 2 
PAX6 Paired Box 6 
PET1 (FEV) FEV (ETS oncogene family) 
PITX3 Paired-Like Homeodomain 3 
PPARD Peroxisome proliferator-activated receptor delta 
PPP1R15A Protein Phosphatase 1, Regulatory Subunit 15A 
PPP1R15B Protein Phosphatase 1, Regulatory Subunit 15B 
RALDH2 (ALDH1A2) Aldehyde dehydrogenase 1 family, member A2 
RARB Retinoic acid receptor, beta 
RBP1 Retinol binding protein 1, cellular 
RDH10 Retinol dehydrogenase 10 (all-trans) 
RELN Reelin 
RXRA Retinoid X receptor, alpha 
SLC2A14 Solute carrier family 2, facilitated glucose transporter member 14 
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Primer  
(Gene symbol) 
Gene full name 
SOX1 Sox1, SRY (sex determining region Y)-box 1 
SOX2 Sox2, SRY (sex determining region Y)-box 2 
STRA6 Stimulated by retinoic acid 6 
SYP Synaptophysin 
T T Brachyury Transcription Factor 
TBR1 T-box brain 1 
TBX6 T-Box 6 
TH Tyrosine hydroxylase 
TKT Transketolase 
TUBB3 Tubulin, Beta 3 Class III 
 
Table 5. Antibodies used in this study 
Primary Antibody Description Source 
Pluripotency 
OCT-4-A Rabbit IgG Monoclonal StemLight™ 
Pluripotency 
Antibody Kit - Cell 
Signaling 
Technology® 
SOX2 Rabbit IgG Monoclonal 
NANOG Rabbit IgG Monoclonal 
SSEA4 Mouse IgG3 Monoclonal 
TRA-1-60 Mouse IgM Monoclonal 
TRA-1-81 Mouse IgM Monoclonal 
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Three Germ Layers 
β- 3 TUBULIN Chicken Millipore 
DESMIN Mouse Dako 
SOX17 Goat R&D Systems 
Western Blot 
β- Actin Chicken Abcam 
EIF2S3 Rabbit Polyclonal. N-terminal region. Aviva; Abcam 
APOE IgG1 Mouse Novus Bio 
Second Antibodies Description Source 
Anti-Mouse IgM Alexa Fluor® Donkey 568nm Abcam 
Anti-Mouse, Rabbit, 
Chicken, Goat and 
Sheep IgG 
Alexa Fluor® Donkey and Goat 488, 568 
and 647 nm 
Abcam 
Anti-Chicken HRP conjugated Abcam 
Anti-Mouse; Rabbit 800 CW and 680RD LiCOR 
3.3. Cell lines  
The cell lines donated and generated for this study are listed in the Table 6. MH 
stands for MEHMO patient, whereas C refers to clonal line. All MH1 lines belong 
to the same MEHMO patient. 
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Table 6. Cell lines used in this study 
Cell line Genotype, Phenotype Organism 
REF Rat Embryonic Fibroblast - isolated from Day 
E14 Sprague Dawley rat embryos as 
described in (Takahashi and Yamanaka, 2006)  
Rat 
MEF CD-1 Mouse Embryonic Fibroblasts, Day 
E12.5 (StemCell™ Technologies - Vancouver, 
Canada) 
Mouse 
HEK 293T Human Embryonic Kidney 293T for Lentiviral 
Packaging (Takara - Mountain View, CA, USA) 
Human 
HFF Human Foreskin Fibroblasts (System 
Biosciences – Palo Alto, CA, USA) 
Human 
hiPSC Control lines 
K1 Control Male Human 
K3 Control Male Human 
K5 Control Male Human 
hiPSC Patient lines (from same patient) 
MH1 Mixed lines Human 
MH1C1 Clone 1 Human 
MH1C3 Clone 3 Human 
3.4. Media and other solutions 
3.4.1. Bacterial media 
Generally, Luria Bertani Miller Broth (LB) was used for cultivation of E. coli. Super 
Optimal broth with Catabolic repressor (SOC) was used to cultivate E. coli. 
following electroporation. For preparation of agar plates, agar in a concentration 
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of 15 g/L was added to LB medium. Media were prepared with deionized water 
and autoclaved for 20 minutes at 121°C, whereas thermo-sensitive solutions 
were sterilized by filtration with 0.2 µm pore size filters (Millipore - Darmstadt, 
Germany). All bacterial media used in this study are listed in Table 7.  
 
Table 7. Media used for cultivation of E. coli strains 
 
Medium 
 
Composition 
LB 1% Tryptone 
0.5% Yeast extract 
1% NaCl 
SOC 2% Peptone 
0.5% Yeast extract 
10mM NaCl 
2.5mM KCl 
10mM MgCl2 
10mM MgSO4 
20mM Glucose 
For selection of resistant bacteria, Ampicillin (Ap) was added to the media to a 
final concentration of 100 μg/mL. Antibiotic was dissolved in deionized water and 
sterilized by filtration with 0.2 µm pore size filters (Millipore). 
3.4.2. Mammalian cell culture media 
All media supplements that required previous dilution were sterilized by filtration 
with 0.2 µm pore size filters (Millipore). All mammalian cell media and 
supplements used in this study are listed in Table 8 and Table 9. 
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Table 8. Media used for cultivation of mammalian cell lines. 
 
Medium 
 
Composition 
MEF/REF/HEK293T Dulbecco's Modified Eagle Medium (DMEM) - Life Technologies 
15% Fetal Bovine Serum (FBS) - Life Technologies 
1% Antibiotic-Antimycotic - Gibco™  
2 mM GlutaMAXTM - Life Technologies 
100 μM Nonessential amino acids (NEAA) - Life Technologies 
HFF Dulbecco's Modified Eagle Medium (DMEM) - Life Technologies 
10% Fetal Bovine Serum (FBS) - Life Technologies 
1% Antibiotic-Antimycotic - Gibco™  
2 mM GlutaMAXTM - Life Technologies 
100 μM Nonessential amino acids (NEAA) - Life Technologies 
Keratinocytes EpiLife® Medium, with 60 µM calcium - Gibco™ 
1X Human Keratinocyte Growth Supplement (HKGS) - Gibco™ 
10µM ROCK Inhibitor (Ascent Scientific, Avonmouth, BS, UK) 
Reprogramming  EpiLife® Medium, with 60 µM calcium - Gibco™ 
1X Human Keratinocyte Growth Supplement (HKGS) - Gibco™ 
8 μg/mL Polybrene (Sigma-Aldrich®) 
10µM ROCK Inhibitor - Ascent Scientific 
Codon-optimized OKSM red virus suspension 
hiPSC Knockout™ DMEM - Gibco™ 
1% Antibiotic-Antimycotic - Gibco™  
20% KnockOut™ Serum Replacement - Gibco™ 
2 mM GlutaMAXTM - Life Technologies 
100 μM Nonessential amino acids (NEAA) - Life Technologies 
100 μM Beta-mercaptoethanol - Gibco™ 
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hiPSC (cont.) 50μg/mL L(+)-Ascorbic acid - Carl Roth® 
10µM ROCK Inhibitor - Ascent Scientific 
10 ng/mL Recombinant Human FGF-2 - Cell Guidance Systems 
(Cambridge, UK) 
FTDA (based on (Frank 
et al., 2012)) 
 
DMEM/F-12, GlutaMAX™ supplement - Gibco™ 
1% Antibiotic-Antimycotic - Gibco™ 
0.1% Human Serum Albumin (HSA) - Biological Industries 
(Kibbutz Beit-Haemek, Israel) 
1:100 Chemically Defined Lipid Concentrate - Life Technologies 
5ug/mL Insulin, 5ug/mL Transferrin, and 5ng/mL Selenious Acid 
(ITS Premix) - Corning® (NY, USA) 
5 ng/mL Activin A- Cell Guidance Systems 
10 ng/mL Recombinant Human FGF-2 - Cell Guidance Systems 
0.5 ng/mL Recombinant Human TGF-β1 - Peprotech (Rocky Hill, 
NJ, United States) 
50 nM Dorsomorphin (Compound C) – Abcam (Cambridge, UK) 
SILAC base medium 
(FTDA adapted for 
SILAC) 
DMEM:F12 (1:1) Media for SILAC – Thermo Fisher Scientific™ 
1% Antibiotic-Antimycotic - Gibco™ 
0.1% Human Serum Albumin (HSA) - Biological Industries 
1:100 Chemically Defined Lipid Concentrate - Life Technologies 
1X GlutaMAX™ Supplement - Gibco™ 
5ug/mL Insulin, 5ug/mL Transferrin, and 5ng/mL Selenious Acid 
(ITS Premix) - Corning® 
5 ng/mL Activin A- Cell Guidance Systems 
10 ng/mL Recombinant Human FGF-2 - Cell Guidance Systems 
0.5 ng/mL Recombinant Human TGF-β1 - Peprotech 
50 nM Dorsomorphin (Compound C) - Abcam 
EB´s  PeproGrow hESC Embryonic Stem Cell Media - Peprotech 
10µM ROCK Inhibitor - Ascent Scientific 
10µM (±)-Blebbistatin - Abcam 
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hESC DMEM/F-12, GlutaMAX™ supplement - Gibco™ 
1% Antibiotic-Antimycotic - Gibco™  
20% KnockOut™ Serum Replacement - Gibco™ 
100 μM Nonessential amino acids (NEAA) - Life Technologies 
100 μM Beta-mercaptoethanol - Gibco™ 
N1M DMEM/F-12, GlutaMAX™ supplement - Gibco™ 
1% Antibiotic-Antimycotic - Gibco™ 
1X Hormonmix (Table 9) 
1X B-27® Supplement (50X), serum free - Gibco™ 
2µM Dorsomorphin (Compound C) - Abcam 
N2M DMEM/F-12, GlutaMAX™ supplement - Gibco™ 
1% Antibiotic-Antimycotic - Gibco™ 
1X Hormonmix (Table 9) 
1X B-27® Supplement (50X), serum free - Gibco™ 
2µM Dorsomorphin (Compound C) - Abcam 
10 ng/mL Recombinant Human FGF-2 - Cell Guidance Systems 
N3M DMEM/F-12, GlutaMAX™ supplement - Gibco™ 
1% Antibiotic-Antimycotic - Gibco™ 
1X Hormonmix (Table 9)  
1X B-27® Supplement (50X), serum free - Gibco™ 
2µM Dorsomorphin (Compound C) - Abcam 
10 ng/mL Recombinant Human FGF-2 - Cell Guidance Systems 
10 ng/mL Recombinant Human Epidermal growth factor (EGF) - 
Cell Guidance Systems 
N4M 50% DMEM/F-12, GlutaMAX™ supplement - Gibco™ 
50% Neurobasal® Medium - Gibco™ 
1% Antibiotic-Antimycotic - Gibco™ 
1X Hormonmix (Table 9) 
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N4M (cont.) 1X B-27® Supplement (50X), serum free - Gibco™ 
1mM Dibutyryl-cAMP - ENZO (Lörrach, Germany) 
200µM L(+)-Ascorbic acid - Carl Roth® 
10ng/mL Recombinant Human Glial-derived Neurotrophic Factor 
(GDNF) - Cell Guidance Systems 
10ng/mL Recombinant Human Brain-derived Neurotrophic 
Factor (BDNF) - Cell Guidance Systems 
 
Table 9. Hormonmix supplement used for cultivation in neuronal differentiation. 
 
Hormonmix Composition (50X) 
24nM Sodium selenite 
16nM Progesterone 
80 µg/mL Holotransferrin 
20 µg/mL Insulin 
87.58µM Putrescin 
 
Antibiotics were added to media to the final concentration described in Table 10. 
For selection of resistant cell lines, Puromycin (Puro) and Geneticin (G418) from 
Thermo Fisher Scientific™ were applied, while Doxycycline (DOX) from Sigma-
Aldrich® was used in case of inducible gene expression system application. 
 
Table 10. Antibiotics used in this study. 
Antibiotics Final concentration 
Puromycin 1µg/mL 
Geneticin 800µg/mL 
Doxycycline 1µg/mL 
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3.5. Mammalian cell culture 
All cell lines were incubated at 37°C, 5%O2; 5% CO2 and 95% relative air humidity 
(Heracell™ 240iCO2 Incubator). If not otherwise indicated, cells were centrifuged 
at room temperature and 400xg for 2 min (Thermo Fisher Scientific™ Heraeus™ 
Megafuge™ 16R Centrifuge).  
Thawing of frozen cell cryogenic vials, as well as media warming were performed 
on a water bath (Thermo Fisher Scientific™) at 37°C. For cells washing steps 
Dulbecco's phosphate-buffered saline (PBS) no calcium, no magnesium 
(Gibco™) was used. If not otherwise mentioned, all flasks and plates used to 
cultivate the cells were tissue culture treated and purchased by Corning®.  
Cell lines were frozen using specific media and deposited on cryogenic vials 
(Corning® cryogenic vials, internal thread). Cryogenic vials were gradually frozen 
in Cryo-Safe™ -1°C Freeze Controller containers (SP Scienceware™) at -80°C 
overnight, to be further stored in liquid N2 tank (CryoPlus2 - Thermo Fisher 
Scientific™). 
3.5.1. MEF/REF/HEK293T/HFF culture 
MEF (Mouse Embryonic Fibroblasts); REF (Rat Embryonic Fibroblasts), HEK 
293T (Human Embryonic Kidney 293T) and HFF (Human Foreskin Fibroblasts) 
sources are described on Table 6 .For their culture, a vial of frozen cells was 
rapidly thawed and immediately transferred into 10 mL of medium (see Table 8). 
Cells were centrifuge and pellet was resuspended in 15mL medium, which was 
plated on a T75 flask and incubated. Medium was changed every second day. 
3.5.1.1. MEF conditioned medium 
In order to prepare MEF conditioned medium, MEF cells were cultivated as 
described on previous section to 100% confluence and split 1:3. Two days after 
splitting, medium (see Table 8) was collected (at this stage cells should be 
approximately 60% confluent), filtered using a 0.2µm sterile filter (Millipore) and 
stored at -20°C (long term) or at 4°C.  
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3.5.1.2. Lentivirus production 
For lentivirus production, a number of 4-5 x 106 low passage HEK293T cells was 
plated in a 10 cm2 dish (Cell Star®) using 10 mL HEK medium (Table 8), one day 
before transfection. At the day of transfection, a mixture of plasmid DNA was 
prepared with 400µL Opti-MEM® (Life Technologies), 8µg vector with gene of 
interest, 5.5µg pSPAX2, 2µg pMD2.G and 70µg Linear polyethylenimine 
(Polysciences, Inc.). The mixture was incubated at RT for 10min, then 1mL of 
DMEM was added. Cells medium was replaced by 6.5mL DMEM (Life 
Technologies) and the mixture preparation was drop wise added, promoting an 
even distribution. Cells were incubated for 4h and medium was replaced with 8mL 
HEK medium. At the second day after transfection medium was collected and 
stored at 4°C. New 8mL HEK medium was once more given to the cells, which 
were incubate again. Medium was collected in the fourth day after transfection, 
and mixed with the previously collected medium to be centrifuged (RT;400xg; 
2min). In order to separate the remaining cells, the supernatant was filtered using 
a 0.45µm sterile filter (Millipore). Concentration was made by mixing the virus 
solution and Lenti-X™ Concentrator (Clontech Laboratories, Inc - Mountain View, 
CA, USA) in a ratio of 1:3 by volume. The mixture was incubated at 4°C overnight 
and centrifuged the day after (4°C; 1,500xg; 45min). Supernatant was discarded 
and virus was resuspended with 1mL of appropriate medium (DMEM/F-12, 
GlutaMAX™ supplement - Gibco™ or EpiLife® Medium, with 60 µM calcium - 
Gibco™). Virus 100µL aliquots (5x108 proviral copies) were stored at -80°C for 
later usage. 
3.5.2. Keratinocytes generation and culture 
Keratinocytes were isolated from donated patient and control plucked hairs 
presenting a healthy outer root sheath. Those hair roots were either kept on 
DMEM (Life Technologies) at RT for transportation or immediately used for 
plating. For plating of hair roots, T25 flasks were coated using Matrigel® 
Basement Membrane Matrix, LDEV-Free, (Corning®) diluted 1:5 in EpiLife® 
Medium, with 60 µM calcium (Gibco™) supplemented by 1X HKGS (Gibco™). 
Flasks were incubated for 1h. Hair roots were placed on the top of the coated 
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flask surface and one drop of the same matrigel used to coat was carefully given 
to the root in a 1:10 dilution. The flask was again incubated for 2h. After the 
incubation time, 1mL of MEF conditioned medium (see sections 3.5.1.1 and 
3.5.1.2) supplemented by 10ng/mL FGF2 (Peprotech), 10µM ROCK Inhibitor 
(Ascent Scientific) and 50 µg/mL ascorbic acid (Sigma-Aldrich®) was carefully 
added to the hair and the flask incubated. MEF conditioned medium 
supplemented was daily changed and when the first keratinocytes emerging out 
of the outer root sheath were observed, the medium was changed to 
keratinocytes medium (see Table 8). 
Once the keratinocytes flask was confluent, 400 µL of Dispase (Corning®) was 
given to the flask and incubated for 10 min. Cells were collected with PBS and 
centrifuged. 
To freeze keratinocytes, Synth-a-Freeze® Cryopreservation Medium (Gibco™) 
was used. 
In case of further culture, keratinocytes pellet was resuspended in keratinocytes 
medium (see Table 8) and plated on a previously coated 6-well format plate. For 
coating, collagen from human placenta Type IV (Sigma-Aldrich®) was diluted in 
PBS to a final concentration of 20μg/mL and plate was incubated for 1h.  
3.5.3. Human induced pluripotent stem cells generation 
The patient lines MH1, MH1C1 and MH1C3 were generated thanks to the kindly 
patient hair sample donation. Control cell lines K1, K3 and K5 originate from hair 
(keratinocytes) provided by healthy donors. All lines were generated at the 
Institute of Neuroanatomy and Developmental Biology of the Eberhard Karls 
University Tübingen. 
3.5.3.1. Keratinocytes reprogramming preparation 
For keratinocytes reprogramming, keratinocytes were cultivated as described in 
section 3.5.2 to a confluence of 70% (~ 3x105 cells). At least one day before 
starting the transduction, mitotic inactivated REF cells were prepared to serve as 
feeder layer for the reprogramming. 
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3.5.3.2. REF cells mitotic inactivation 
REF cells mitotic inactivation was initiated when the culture achieved a 
confluence of 90-100% (see section 3.5.1). Old medium was discarded and cells 
were treated with 7.5 µg/mL mitomycin C (Biomol - Hamburg, Germany) in fresh 
REF medium (see Table 8). Posteriorly, cells were incubated for 2.5h. After 
treatment, cells were washed three times in PBS and detached using 1X 
TrypLE™ Express Enzyme (Gibco™), as usual. 
For reprograming, 3 wells (6-well format plate) were plated with 1.5 x 105 treated 
REF cells per well. 
3.5.3.3. Reprogramming and culture of hiPSCs 
At the day of reprogramming, keratinocytes well was washed with PBS and 
medium was changed to reprogramming medium (see Table 8). Cells were 
incubated overnight and the same procedure was repeated on the following day. 
On the third day of reprogramming, keratinocytes were detached with 1X 
TrypLE™ Express Enzyme (Gibco™), centrifuged, resuspended on hiPSC 
medium (see Table 8) and split 1:3. Cells were plated on the three previously 
prepared REF feeder wells (see section 3.5.3.2). hiPSC medium was daily 
changed. 
After approximately 10 days, hiPSCs-like colonies normally arise from the 
transduced keratinocytes. At this stage the colonies were transferred into a 
feeder-free system. To transfer the colonies, wells (6-well format plate) were 
coated using Matrigel® hESC-Qualified Matrix, LDEV-Free (Corning®) diluted 
according to manufacturer’s instructions and incubated for 1h. With the help of a 
pipette, colonies were scratched and carefully transferred into the previously 
coated well with 1.5mL FTDA medium (see Table 8). For clonal lines, a single 
small colony was separately transferred.  
In order to further culture and expand cells, they were washed in PBS and 
incubated for 2 minutes in Dispase in Hank's Balanced Salt Solution Modified 
(StemCell™ Technologies) diluted 1:5 in DMEM/F-12, GlutaMAX™ supplement 
(Gibco™) for splitting. After incubation, cells were washed in PBS and FTDA 
medium was given to them. Cells were detached with the help of a cell spatula 
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(TPP® - Trasadingen, Switzerland) and small colony clumps were plated in 
previously coated wells, as described before.  
3.5.3.4. Freezing and thawing hiPSCs 
To freeze, cell colonies were detached as for splitting (see section 3.5.3.3). 
Scratched colonies were centrifuged and cell pellet was resuspended in 
CryoStem™ Freezing Medium (Biological Industries) to be frozen. 
Thawing of the frozen cryogenic vial was performed by incubation in water bath 
and immediate resuspention in 10mL FTDA medium. Cells were centrifuged, 
supernatant discarded and pellet was ressuspended in fresh FTDA for plating in 
a previously coated well (see section 3.5.3.3). 
3.6. Generation of overexpression HFF cell lines 
Generation of EIF2S3 wild-type and mutant (I222T mutation on EIF2S3) HFF 
overexpression lines, required cloning of the gene of interest into a lentiviral 
vector (pLVX-TRE3G), as described in sections 3.11 and 4.4.1. Lentivirus 
production was accomplished by using pSPAX2 and pMD2.G (Table 2), as it is 
described in the previous section 3.5.1.2. 
Two days prior to HFF (Table 6) infection, cells were usually split (section 3.5.1). 
At the day of infection, cells were washed twice with PBS and 5mL of HFF 
medium (Table 8) supplemented with 10µM ROCK Inhibitor (Ascent Scientific), 8 
μg/mL Polybrene (Sigma-Aldrich®) and virus suspension of interest was given to 
each well. Cell plate was centrifuged (RT; 1,000xg; 30 min) and incubated for 4h. 
Following incubation period, medium was discarded and fresh HFF medium was 
given. The infection process was equally repeated at the following day and cells 
were normally culture and further selected. Infected cells were selected by 
addition of either Puromycin or Geneticin (Table 10) to the culture for 3 to 4 days. 
Cells infection with Lenti-X™ Tet-On® 3G Inducible Expression System (Clontech 
Laboratories, Inc) required a double infection with virus originated from the 
response plasmid (pLVX-TRE3G-4291 or pLVX-TRE3G-4292) and from the 
regulator plasmid (pLVX-Tet3G). The control line was infected with the regulator 
plasmid and an empty response plasmid. 
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3.7. Generation of knock-down HFF cell lines 
Generation of EIF2S3 knock-down HFF line, required lentivirus production 
(section 3.5.1.2) using pSPAX2 and pMD2.G (Table 2) and a pTRIPZ lentiviral 
inducible shRNA (Clone ID: V3THS_395443) expression vector (Open 
Biosystems). 
Two days prior to HFF (Table 6) infection, cells were, as usually, split (section 
3.5.1). At the day of infection, cells were washed twice with PBS and 5mL of HFF 
medium (Table 8) supplemented with 10µM ROCK Inhibitor (Ascent Scientific), 8 
μg/mL Polybrene (Sigma-Aldrich®) and virus suspension of interest was given to 
each well. Cell plate was centrifuged (RT; 1,000xg; 30 min) and incubated for 4h. 
Following incubation period, medium was discarded and fresh HFF medium was 
given. The infection process was equally repeated at the following day and cells 
were normally culture and further selected. Infected cells were selected by 
addition of Puromycin (Table 10) to the culture for 3 to 4 days. The control line did 
not present any construct. 
3.8. Three germ layers differentiation 
In order to demonstrate hiPSC lines pluripotency, three germ layers differentiation 
was carried out. At first day of differentiation a confluent plate (6-well format) of 
the hiPSCs was washed with PBS and FTDA medium was given to them. Cells 
were collected, centrifuged and ressuspended in 10mL hESC medium (Table 8) 
supplemented by 10µM ROCK Inhibitor (Ascent Scientific). Cells were transferred 
into a T25 flask to form Embryoid Bodies (EB´s), and medium was partially 
changed every two days with 8mL hESC medium without Rock Inhibitor for 10 
days. At the eleventh day both 12-well and 24-well format plates were coated with 
Matrigel® hESC-Qualified Matrix, LDEV-Free (Corning®), diluted according to 
manufacturer’s instructions, and incubated for 1h. Being the 24-well format plated 
for staining purposes, coverslips Ø 13mm, thickness I (Neolab - Heidelberg, 
Germany) were placed inside the wells previously to the coating. After the 
incubation period, 2 to 4 EB´s were plated using 1 mL hESC medium. Medium 
was daily changed and cells were cultivated for 10 more days. Thereafter cells 
were either harvested for RNA isolation or forwarded for immunostaining. 
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3.9. Undirected neuronal differentiation 
Based on Kim et al. 2011 (Kim et al., 2011), undirected neuronal differentiation 
started with treatment of hiPSCs with 1X TrypLE™ Express Enzyme (Gibco™) 
for about 5 minutes on incubator to create a single cell suspension. After 
incubation, some FTDA medium (see Table 8) was given to the cells. At this point, 
cells were counted for a total of 20.000 cells per well (96-well format plate). 
Medium was discarded and EB´s medium (see Table 8) was added, according to 
the calculated volume. Cells were plated on a 96-well conical bottom plate 
(Sarstedt - Nümbrecht, Germany) and incubated for two consecutive days. On 
the third day, medium was changed to N1M (see Table 8) and cells were once 
more incubated for two consecutive days. To plate the formed EB´s on the fifth 
day, a 6-well format plate was coated with Matrigel® hESC-Qualified Matrix, 
LDEV-Free (Corning®), diluted according to manufacturer’s instructions, and 
incubated for 1h.  
Most of the matrigel was discarded and the EB´s were plated using N2M medium 
(Table 8). EB´s were further cultivated until the formation of neural “rosettes”. This 
step usually lasted from 2 to 7 days and N2M was daily changed. Once the neural 
“rosettes” were formed, the old medium was discarded and fresh N3M (Table 8) 
was added. Cells were detached mechanically by carefully pipetting medium on 
them. All neural “rosettes” were transferred into an ultra-low attachment 25cm2 
flask (Corning®) in a total volume of 10mL N3M. Medium was changed each 
second day during eleven days.  
Thereafter, the formed neurospheres of neural stem cells (NSCs) were plated in 
coated wells using N4M medium (Table 8). Coating had two phases, each 1h in 
the incubator. The first phase required covering of the surface with enough 
volume of 10 µg/mL Poly-L-ornithine (Sigma-Aldrich®). In the second step, Poly-
L-ornithine solution was discarded, well was washed in PBS twice and coated 
with enough volume of 5 µg/mL Laminin (Roche - Basel, Switzerland). 
Occasionally, when neurospheres were remarkably large, a previous treatment 
with StemPro Accutase Cell Dissociation Reagent (Life Technologies) for 5 
minutes was appropriate. 50% of the medium volume was carefully changed 
every second day. Cells were cultivated for three or four weeks, when they were 
used for further analysis. 
  
42 
 
3.10. Bacterial cells manipulation 
3.10.1. Bacterial culture conditions 
Inoculum of E.Coli strains of interest were cultivated either in tubes containing 
4mL of LB medium or in 1L baffled flasks containing 300 mL of LB medium (see 
Table 7). In both cases the culture was supplemented by 100 μg/mL ampicillin, if 
appropriate. The cultures were incubated overnight at 37°C and 160rpm (Shaking 
Incubator with orbital motion, GFL - Hannover, Germany). Cultivation on solid 
medium (LB with agar and, if appropriate, 100 μg/mL ampicillin) was carried out 
after transformation of E. coli (see section 3.10.4) and was also incubated 
overnight at 37°C. 
3.10.2. Conservation of E.Coli strains 
In order to preserve bacterial strains, glycerol cultures were prepared giving 
400μL liquid culture to 600μL glycerol (87%). Cultures were stored at -80°C and 
to cultivate them again, the glycerol stock was thawed on ice and 10µL of the 
stock was inoculated into a new LB culture flask. 
3.10.3. Preparation of electrocompetent E. coli  
The preparation of competent cells started with an initial culture of 5mL of LB 
medium (see Table 7) from a glycerol stock of E. coli DH5α (Table 2). The culture 
was incubated overnight at 37°C and 125rpm (Shaking Incubator with orbital 
motion, GFL), and on the following day it was used to inoculate 300mL of LB 
medium to an OD600 of 0.1. Bacteria were left growing at 37°C and 160rpm 
(Shaking Incubator with orbital motion, GFL) to reach an OD600 of 0.35-0.4. At this 
point, culture was placed on ice for 30 minutes. Thereafter, cell culture was 
centrifuged (1,000xg, 4°C, 20 min) and supernatant discarded. Cell pellet was 
resuspended in 240mL of cold H2Odest and cells were harvested again by 
centrifugation (1,000xg, 4°C, 20 min). Cells were once more rinsed in 120mL of 
cold H2Odest and centrifuged as described before. In the last washing step, cells 
were rinsed on 24mL of cold 10%glycerol solution. After centrifugation, pellet was 
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finally resuspended in 600µL of cold 10% glycerol solution and aliquots of 100µL 
were stored at -80°C. 
3.10.4. Transformation of electrocompetent E. coli  
To transform E. coli, 1-2µg of the plasmid of interest was added to an aliquot of 
100µL competent E. coli (see section 3.10.3) previously thawed on ice. 
Thereafter, bacterial suspension was transferred into a pre-chilled electroporation 
cuvette (PeqLab – Erlangen, Germany) and pulsed using a Gene-Pulser II (Bio-
Rad – Munich, Germany). The expected pulse length was close to 5 ms and the 
settings applied: 1.8kV, 25µF and 600Ω. Immediately after electroporation, 800µL 
SOC medium (see Table 7) was given to the bacteria, which was incubated at 
37°C, 500rpm for 1hour (Thermomixer pro - Cell Media - Elsteraue, Germany). 
Following incubation, bacteria was harvest by centrifugation (3 minutes at
1,000xg) and plated on a LB plate (supplemented with antibiotic, if necessary – 
see section 3.10.1) and incubated overnight at 37°C. 
3.11. DNA techniques 
All centrifugation steps were performed in a microcentrifuge (Thermo Fisher 
Scientific™ Heraeus™ Fresco™) and, if not otherwise indicated, incubations took 
place in an orbital shaker (Thermomixer pro - Cell Media). 
3.11.1. Plasmid isolation from E. coli. 
For amplification and isolation of plasmid DNA, transformed E.Coli cells were 
cultivated (see section 3.10.1). Cells were harvested by centrifugation (1 min, 
11,000xg) and plasmid isolation was carried out, as recommended by the 
supplier, using either JetQuick Plasmid Miniprep Spin kits (GENOMED GmbH) or 
NucleoBond® Xtra Maxi EF (Macherey-Nagel). The isolation kit was chosen 
according to the amount of plasmid required. 
3.11.2. Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) was performed in a thermocycler (PERKIN 
ELMER DNA Thermal Cycler 480) according to the protocol described below. 
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Primers (Table 3) were provided by biomers.net GmbH and diluted in H2Odest. to 
a final concentration of 100 pmol/μL. The melting temperature (Table 3), 
temperature at which 50% of the oligonucleotides form double strand, was 
calculated by the manufacturer, considering salt concentration, oligonucleotides 
composition and concentration. 
For a PCR reaction assay, 5ng of template DNA was mixed to 10μL 5x Prime 
STAR GXL Buffer, 4μL 2.5 mM dNTP mixture (Takara), 1.5μL 10µM primer 
forward, 1.5μL 10µM primer reverse and 1μL Prime STAR GXL DNA Polymerase 
(Takara). H2Odest. was added, if necessary, to complete 50μL of reaction volume. 
All reaction parameters were set according to the enzyme supplier´s 
recommendations. PCR conditions consisted of 30 successive cycles of 
denaturation (98°C for 10 seconds), annealing (60°C for 15 seconds) and 
elongation (68°C for 90 seconds). PCR products were analyzed by agarose gel 
electrophoresis (see section 3.11.3). 
3.11.3. Gel electrophoresis  
As a mean of separating different sizes of DNA fragments, electrophoresis gels 
were prepared with 1% agarose diluted in 1X TAE buffer (Table 11) and 
supplemented with 1X GelGreen™ Nucleic Acid Gel Stain, 10,000X in DMSO 
(Biotium - Fremont, CA, USA). DNA samples were mixed with 6x DNA loading 
buffer and applied on the gels, always besides a MassRuler Express Forward 
DNA Ladder Mix 10kb (Thermo Fisher Scientific™), used as DNA size reference. 
Electrophoresis was performed in an Bio Rad apparatus (Bio-Rad) set to 100V. 
 
Table 11. Gel electrophoresis buffers 
 
Solution 
 
Composition 
50 X TAE Buffer (1L) 2M Tris 
50 mM EDTA 
57.1mL acetic acid, pH 8.5 
1 X TAE Buffer  50 x TAE buffer diluted in H2Odest. 
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Solution 
 
Composition 
6X DNA loading buffer 0.25% (w/v) bromphenol blue 
0.25% (w/v) xylene cyanol FF 
40% (w/v) sucrose 
3.11.4. DNA extraction from agarose gels 
Agarose gel containing GelGreen™ (Biotium) allowed the visualization of DNA by 
UV radiation (366nm). The fragments of interest were excised with a scalpel, and 
DNA extraction from the gel was carried out with JetQuick Gel Extraction Spin kit 
(Genomed GmbH) according to the supplier´s instructions. DNA concentrations 
were determined in the NanoPhotometer® P-Class 330 (IMPLEN - Munich, 
Germany). Purity was accessed by determination of the quotient of A260 / A280, 
which ranges between 1.8 and 2.0 for pure DNA.  
3.11.5. Restriction of DNA 
Cloning of DNA fragments into vectors requires compatible ligation sites created 
by restriction of specific sequence in both fragment and vector. Therefore, 
treatment with one or two restriction enzymes, as recommended by the supplier, 
was accomplished. To avoid re-ligation of vectors during the first restriction, 
FastAP alkaline phosphatase (Thermo Fisher Scientific™) was added to the 
reaction. A general restriction protocol included up to 1μg chromosomal or 
plasmid DNA, 1X FastDigest buffer, 1μL restriction enzyme I, 1μL restriction 
enzyme II (optional) and H2Odest., if necessary, to complete 20μL of reaction 
volume. The reaction volume was scaled up appropriately according to the needs. 
For following ligation, DNA was purified after restriction by gel electrophoresis 
and extraction (sections 3.11.3 and 3.11.4). For control restriction, DNA was 
further analyzed by gel electrophoresis (section 3.11.3). 
3.11.6. Ligation (Cloning of restriction enzyme generated fragments) 
The last step in cloning required the ligation of the restricted DNA fragment and 
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vector by T4 DNA Ligase enzyme. The reaction was composed by a 3:1 insert 
fragment molar ratio over vector, 1x T4 DNA Ligase buffer, 1μL T4 DNA Ligase 
and H2Odest., if necessary, to complete 20μL of reaction volume. Ligation reaction 
was carried out for 1 hour at 22°C and either frozen at -20°C for further use or 
directly used for E.Coli transformation (see section 3.10.4). 
3.11.7. DNA Sequencing 
All cloned vectors were sent to GATC Biotech (Konstanz, Germany), together 
with the appropriated sequencing primer (Table 3). To verify the fidelity of the 
cloning process, FinchTV software (Geospiza, Inc., Seattle, USA) was used for 
genomic comparison. 
3.12. RNA techniques 
All centrifugation steps, if not otherwise indicated, were performed in a 
microcentrifuge (Thermo Fisher Scientific™ Heraeus™ Fresco™). 
3.12.1. RNA isolation from mammalian cells. 
RNA extraction was performed using RNeasy Mini® kit (QIAGEN). For this 
purpose, cells were washed in PBS and harvested by centrifugation (2min, RT; 
400xg) (Thermo Fisher Scientific™ Heraeus™ Megafuge™ 16R Centrifuge). Cell 
pellet was ressuspended in RLT buffer according to cell number, and isolation 
was performed following supplier´s instructions. RNA was eluted in up to 60μL 
RNAse-free H2O and concentrations were determined in the NanoPhotometer® 
P-Class 330 (IMPLEN). Purity was accessed by determination of the quotient 
A260/A280, which is 2.0 for pure RNA.  
3.12.2. Quantitative real-time PCR (qRT-PCR) 
Quantitative analysis of gene expression was possible by the real-time 
polymerase chain reaction of RNA samples. Initial RNA reverse transcription was 
followed by PCR, allowing quantification to be accomplished in one step. 
Quantification of different targets was done by binding of SYBR Green I 
fluorescent dye to double-stranded DNA molecules, emitting a fluorescent signal. 
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This way, target RNA amounts can be measured in a real-time modus, as the 
DNA copies are being produced. 
The reaction made use of QuantiTect® primers (QIAGEN) (Table 4) and 
QuantiFast® SYBR® Green RT-PCR kit (QIAGEN), according to manufacturer’s 
instructions. 
Reference genes HMBS, GAPDH and G6PD were empirically found to be the 
best for the cell types analyzed, due to their constant transcription considering 
the experimental conditions.  
Experiment was run in the Applied Biosystems StepOneTM Real-Time PCR 
System and StepOneTM Software v2.3 was the software of choice to obtain the 
raw data in cycle threshold (Ct) values, which were used to calculate the amount 
of initial mRNA, as described by Livak and Schmittgen, 2001 (Livak and 
Schmittgen, 2001). 
3.12.3. qRT-PCR array - FLUIDIGM® 
Besides the usual qRT-PCR, high throughput gene expression analysis was 
accomplished by a special cycler, the BioMark™ HD (Fluidigm® - South San 
Francisco, CA, USA), in which smaller amounts of samples are needed and many 
different genes are analyzed simultaneously.  
Preparation started by reverse transcription of RNA samples into cDNA. DNA 
impurity was removed by treatment of 320ng RNA (sample volume of 9µL) with 
0.25µL DNaseI (Sigma-Aldrich®) and 1µL DNaseI Reaction Buffer (Sigma-
Aldrich®) for 15minutes at room temperature. Following incubation, enzyme was 
inactivated by the adding of 1µLStop solution (Sigma-Aldrich®) to the reaction. 
For cDNA synthesis, 2.75µL of the previous reaction (80ng) was mixed with 1µLof 
5XRT Buffer (Promega - Wisconsin, USA), 0.25µL of dNTPs (GE Healthcare Life 
Sciences), 0.313µL Hexanucleotides mix (Roche), 0.25µL MMLV RT (Promega) 
and 0.438µL RNase free H2O. The reaction tube was incubated at 37°C for 60 
minutes and at 85°C for 10 minutes. cDNA was stored at 4°C or already used for 
preamplification. The preamplification step was useful to increase number of DNA 
copies and facilitate detection of low-expression genes.  
Preamplification was prepared employing PreAmp Master Mix (Fluidigm®) 
according to manufacturer’s instructions, but applying a different assay, the 
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QuantiTect® primer assays (QIAGEN) in a final concentration of 500nM and the 
80ng of previously synthetized cDNA. After this step, samples were treated to 
remove unincorporated primers by using Exonuclease I (New England BioLabs - 
Ipswich, Massachusetts, USA). To this purpose the final 5µL volume 
preamplification assay was mixed with an earlier prepared solution containing 1.4 
µL PCR certified H2O (TEKnova - Hollister, CA, USA), 0.2µL Exonuclease I 
Reaction Buffer and 0.4µL Exonuclease I at 20Units/µL. The reaction was 
incubated at 37°C for 30min and enzyme inactivated by further 15min incubation 
at 80°C. To the 7µL samples, 43µL TE Buffer (TEKnova) was added and stored 
at -20°C for later usage. 
At the following day, 2.7µL of the stored treated samples were well mixed to 3µL 
2XSsoFast EvaGreen Supermix with Low ROX (Bio-Rad) and 0.3µL 20XDNA 
Binding Dye Sample Loading Reagent (Fluidigm®). Sample mixture was 
centrifuged for 30 seconds and temporarily stored at 4°C. A second mix was 
prepared by adding 2.5µL 2XAssay Loading Reagent (Fluidigm®) to 2.5µL of the 
specific QuantiTect® primer assay (QIAGEN), so that assay concentration in this 
mixture was 1000nM. Assay solution was well mixed and centrifuged for 30 
seconds. After both assays and samples mixtures were prepared the 96.96 
Dynamic Array™ IFC was loaded (Fluidigm®) following manufacturer’s 
instructions. The loaded chip was placed into the BioMark™HD (Fluidigm®) reader 
and the thermal cycling protocol for 96.96 Array was selected. After run, reaction 
specificity was evaluated and raw data in cycle threshold (Ct) values collected to 
calculate the amount of initial mRNA, as described by Livak and Schmittgen, 2001 
(Livak and Schmittgen, 2001). The software programs chosen for analysis were 
Fluidigm Real-Time PCR Analysis Software v.3.0.2 and Python software. 
3.13. Protein techniques 
All centrifugation steps were performed in a microcentrifuge (Thermo Fisher 
Scientific™ Heraeus™ Fresco™) and, if not otherwise indicated, incubations took 
place in an orbital shaker (Thermomixer pro - Cell Media). 
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3.13.1. Western Blot 
3.13.1.1 Protein extraction for Western Blot 
For lysis, cells were placed on ice, washed in cold PBS and scratched. After 
centrifugation (2min, 4°C; 400xg), cell pellet was diluted in RIPA Lysis Buffer 
(Table 12). For approximately 2x106-1x107 cells, 60 to 80µL of lysis buffer was 
used. The solubilized cells were transferred into a pre-chilled 1.5mL reaction tube 
and the content was vortexed for few seconds. Thereafter, tubes were moved into 
ultrasonic bath (Transsonic T460/H - ELMA) containing cold water and sonicated 
for 1 minute. Samples were centrifuged for 10 minutes (10,000xg; 4°C) and 
protein supernatant was carefully collected. Protein concentration was 
determined by Pierce BCA Protein Assay Kit (Thermo Fisher Scientific™) 
according to supplier´s instructions. Samples were measured at 562nm in
NanoPhotometer® P-Class 330 (IMPLEN). 
 
Table 12. RIPA Lysis Buffer 
Solution Composition 
RIPA Lysis Buffer 150mM NaCl 
5mM EDTA, pH8.0 
50mM Tris pH8.0 
1% IGEPAL® CA-630 (SIGMA) 
0.5% sodium deoxycholate 
0.1% SDS 
1X Halt™ Protease and Phosphatase Inhibitor Cocktail, EDTA-
Free (Thermo Fisher Scientific™) 
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3.13.1.2 Western Blot 
A qualitative and quantitative analysis of specific proteins in different cell lines 
was performed by western blot. Therefore, the three classical steps for protein 
immunoblot were performed, namely electrophoresis, blotting and protein 
labelling. 
The first step aims a separation by molecular mass of a protein pool, which can 
be further identified by the use of specific antibodies. For the separation to occur, 
the 3D protein structures were unfolded, and equally negatively charged in a 
denaturation process carried out by the addition of a commonly used surfactant 
agent, SDS. Protein samples were prepared by mixing 50µg protein lysate with 
6X SDS loading buffer (Table 13) and H2Odest. for a total volume of 18µL. Samples 
were next incubated for 3 minutes at 95°C. 
Following samples denaturation, a sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed. The mentioned gel consists of two 
phases, an upper region (stacking gel) which stacks the proteins to improve 
resolution separation, and a lower region (resolving gel) where the proteins 
separation itself takes place. Samples were applied in the gel (12% 
Polyacrylamide Mini-PROTEAN® TGX™ Precast Protein Gels – Bio-Rad) and 
next to them, 5µL of a protein molecular weight marker (Chameleon™ Duo - 
LiCOR-928-60000), so that the different protein bands could have their size 
identified. Electrophoresis was carried out in a Mini-PROTEAN Tetra Cell 
apparatus (Bio-Rad) and chamber was filled with 1X Running buffer (Table 13). 
An electrical potential difference of 90V was applied to the samples in order to 
get them stacked in a line and the voltage was increased to 120V to resolve the 
gel. 
After electrophoresis run, separated proteins were blotted in a nitrocellulose 
membrane (Protran BA85 Nitrocellulose Blotting Membrane, 0.45 µm) in wet 
conditions. Therefore, blotting cassette was prepared with gel lying on the 
membrane, ensuring no air bubbles had formed between them. Gel and 
membrane were then sandwiched by a blotting cassette externally sheltered by 
foam pads and internally by two sheets of pre-wetted Whatman® paper (Sigma-
Aldrich®). The blot cassette was clamped tightly together and submerged in 
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blotting chamber containing 1X Wet Transfer buffer (Table 13). Blotting was 
performed by applying 6V/200mA overnight and at 4°C. 
Once blotting was finished, a series of incubations and washing steps were 
performed to stain the protein of interest with specific antibody. To do that, 
membrane was always kept in a petri dish with enough volume to ensure it was 
evenly covered. In all those steps, membrane was placed on a shaker for gentle 
and uniform agitation (IKA® VXR basic Vibrax® - ALDRICH). In order to avoid 
nonspecific binding of antibody, membrane was incubated in blocking solution 
(Table 13) for 2h at room temperature. Blocking solution was discarded and 
membrane was incubated overnight at 4°C with first antibody diluted in blocking 
solution according to supplier´s dilution recommendation.  
On the following day, membrane was washed three times in 1XTBS buffer with 
0.05%Tween20 (Table 13) and incubated in the dark for 1h30min in second 
antibody diluted as recommended by the supplier in blocking solution (Table 5 
and Table 13). After incubation time, second antibody solution was discarded and 
membrane rinsed three times in 1x TBS buffer with 0.05%Tween20 (Table 13). 
The last washing was done using only 1X TBS (Table 13) to remove excess of 
Tween20. 
Membrane was scanned using a near-infrared fluorescence two-color detection 
system, Odyssey® FC (LI-COR), and results analyzed using Image Studio Lite 
version software (LI-COR). After capturing blot image on LiCOR detection 
system, membrane was washed three times with 1x TBS buffer with 
0.05%Tween20 (Table 13), in case of further staining with HRP conjugated 
second antibodies. Therefore, membrane is incubated, as before with blocking 
solution, primary and second antibodies and finally developed using Amersham 
ECL Western Blotting kit (GE Healthcare) according to manufacturer’s 
instructions. Protein bands were once more visualized using Image Studio Lite 
version software (LI-COR). For comparison, the amounts of protein loaded in 
each slot were normalized to those of β-Actin. 
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Table 13. Western Blot buffers and solutions 
Solution Composition 
6X SDS loading buffer 
(pH 6.8) 
 
62mM Tris-HCl; pH6.8 
10% Glycerol 
2% (w/v) SDS  
5% β-mercaptoethanol 
0.00125% Bromphenol blue 
10x Running buffer 
(pH 8.3) 
0.25 M Tris 
1.92 M Glycin 
1% (w/v) SDS 
1x Running buffer 
 
1 part of 10x Running buffer and 9 parts of H2Odest 
 
10x Wet Transfer buffer  
 
250 mM Tris 
1.92M Glycine 
1x Wet Transfer buffer 1 part of 10x Wet Transfer buffer, 2 parts of Methanol and 8 parts 
of H2Odest 
10x TBS Buffer 
(pH 7.5) 
500 mM Tris 
1.5M NaCl 
1x TBS Buffer 
(pH 7.5) 
1 part of 10x TBS Buffer and 9 parts of H2Odest 
1x TBS buffer with 
Tween20 
1x TBS buffer 
0.05%Tween20 
Blocking solution 6% porcine serum (PAA) in 1x TBS buffer 
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3.13.2. Stable isotope labelling by amino acid in culture (SILAC) 
3.13.2.1. Protein extraction for SILAC 
hiPSCs were cultivated as usual (section 3.5.3.3), but using SILAC medium (see 
Table 8 and Table 14). Light proline was supplemented in the three different 
SILAC media due to the metabolic conversion of labelled arginine to labelled 
proline, affecting the final peptides quantification (Lossner et al., 2011). 
After cultivation of hiPSCs for 2 weeks in SILAC medium supplemented by light 
amino acids, cells were split so that wells would be 70% confluent in 48h. The 
splitting was planned to generate one sample out of 2 wells (6-well format). At the 
programed time point, medium was changed into medium labelled and heavy 
labelled medium (Table 8 and Table 14) and cells were incubated for 24h, 16h 
and 6h. After this period, protein was extracted, simultaneously for all samples. 
To that end, 700µL of Lysis Buffer (Table 15) per sample was prepared and placed 
on ice. Cells were placed on ice and washed twice with cold PBS. To scratch the 
cells, Lysis Buffer was added and cells were detached with a cell spatula (TPP®). 
Cells in Lysis Buffer were collected into a 1.5mL reaction tube and kept on ice. 
The tubes were lying on ice, and the ice container was placed in an orbital shaker 
(IKA® VXR basic Vibrax® - Sigma-Aldrich®) at 40rpm for 40 minutes. Tubes were 
centrifuged (4°C; 10,000xg; 10 min) and supernatant was collected into new pre-
chilled tubes. The protein extract concentration was then measured in the 
NanoPhotometer® P-Class 330 (IMPLEN). The pre-selected samples were mixed 
in a 1:1 ratio to proceed with the protein precipitation step. Each precipitate 
sample had a total protein amount of 20µg. 
 
Table 14. Amino acid mixtures supplements to SILAC base medium (see Table 8 ) 
 
Medium 
 
Composition 
Light 0.5M L- proline (Silantes - Munich, Germany) 
0.4M L- arginine (Silantes) 
0.55M L-lysine (Silantes) 
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Medium 
 
Composition 
Medium labelled  0.5M L- proline (Silantes) 
0.4M 13C 6 –arginine (Silantes) 
0.55M 2H 4 –lysine (Silantes) 
Heavy labelled 0.5M L- proline (Silantes) 
0.4M 13C6 15N 4 - L –arginine (Silantes) 
0.55M 13C6 15N2 - L –lysine (Silantes) 
 
Table 15. Buffers for protein extraction in SILAC experiment 
 
Solution 
 
Composition 
10XTBS 
 
1.5 M NaCl 
300 mM Tris 
pH7.4 (adjusted using HCl) 
Lysis Buffer 
 
1X TBS  
0.55% NP-40 Substitute (Sigma-Aldrich®) 
1X Protease Inhibitor Complexe Complete (Roche) 
3.13.2.2. Protein precipitation for SILAC 
After samples were mixed according to the designed experiment, the precipitation 
was executed at room temperature.  
From the protein mix, an aliquot of 200µL was separated. To that aliquot, 800µL 
methanol p.a. v/v=100% (Merck) was added and the tube was vortexed and 
centrifuged at 9,000xg for 30seconds. Next, 200µL chloroform p.a. v/v=100% 
(Merck) was added and the mixture was likewise vortexed and centrifuged. After 
centrifugation, 600 µL HPLC water (Merck) was added, the mixture was vortexed, 
but this time the centrifugation lasted 1minute and revealed both organic and 
aqueous phases. The upper phase was discarded by pipetting the content out 
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and making sure not to touch the interphase with the pipette tip. To the lower 
phase, 600µL methanol p.a. v/v=100% (Merck) was added and the mix was 
smoothly pipetted up and down for two to three times. Thereafter, the tube was 
centrifuged for 5minutes at 16,000xg. Supernatant was carefully discarded and 
protein precipitate was dried under a laminar flow for 5 to 10minutes. Reaction 
tubes containing the pellets were snap-frozen by immersion in liquid nitrogen and 
immediately stored at -80 °C. 
Precipitate samples were sent to German Center for Neurodegenerative 
Diseases (DZNE) within the Helmholtz Association (Tübingen, Germany) for 
further treatment and analysis.  
3.13.2.3. Protein digestion and peptides enrichment 
Protein pellet (20µg per sample) was resuspended in 30µL ABC (Table 16), and 
4 µL Rapi Gest (Table 16) was added to it. Sample was strongly vortexed and 
content was spun down shortly. To the mix, 1µL DTT (Table 16) was added and 
sample was incubated at 60°C for 10minutes. To initiate digestion, sample was 
once more spun down and 2 µL Trypsin Solution (Table 16) was given. Sample 
was then immediately incubated overnight at 37°C; 500rpm. 
On the following day, sample was centrifuged for 1 minute at room temperature; 
9,000xg and the enzymatic reaction was interrupted by adding TFA (Merck) to a 
final concentration of 5%. The solution was transferred into a Polypropylen Insert 
with Bottom Spring; 200µL (SUPELCO - Sigma-Aldrich®), previously placed in a 
1.5mL reaction tube. The tube was incubated for 10 minutes at room temperature 
and subsequently centrifuged at 22°C; 16,000xg for 15 minutes. 
Samples were purified using C18-StageTips (Thermo Fisher Scientific™). To that 
end, the matrix was equilibrated with 20µL 80/5 Solution (Table 16). Matrix was 
next rinsed with 20µL 0/5 Solution (Table 16) and samples were applied. Matrix 
was washed with 20µL 0/5 Solution (Table 16) and the peptides were eluted into 
a new tube, using 20µL 50/5 Solution (Table 16). The remaining peptides were 
eluted again in 20µL 80/5 Solution (Table 16). Eluted samples were concentrated 
to approximately 5µL using Speed Vac® (Savant SPD111V, Thermo Fisher 
Scientific™). 
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Table 16. Solutions used in protein digestion and peptides enrichment. HPLC water 
(Merck) was used in the preparation of all solutions 
 
Solution 
 
Composition 
Amonium bicarbonate 
solution (ABC) 
 
50mM Amonium bicarbonate (Sigma-Aldrich®) 
RapiGest 
 
20mg/mL RapiGest™ SF Surfactant (Waters - Massachusetts, 
USA ) 
Dithiothreitol Solution 
(DTT) 
100mM 1,4-Dithiothreitol (Merck) 
Iodacetamide Solution 
(IAA) 
300mM 2-Iodacetamide (Sigma-Aldrich®) 
Trypsin Solution 1µg/µL Trypsin, Proteomics Grade (Sigma-Aldrich®). Dissolved 
in 1mM HCl (Merck) 
80/5 Solution 5% (v/v) Trifluoracteic acid (TFA) , protein sequencing grade 
(Merck) 
80% (v/v) Acetonitrile, hypergrade for LC/MS (Merck) 
50/5 Solution 5% (v/v) Trifluoracteic acid (TFA) , protein sequencing grade;
(Merck) 
50% (v/v) Acetonitrile, hypergrade for LC/MS (Merck) 
0/5 Solution 5% (v/v )Trifluoracteic acid (TFA) , protein sequencing grade 
(Merck) 
3.13.2.4. Peptides analysis by LC-MSMS 
SpeedVac-dried SEC-Fractions were redissolved in 0.5% TFA and analyzed by 
LC-MSMS using a nano-flow HPLC system (Ultimate 3000 RSLC, Thermo Fisher 
Scientific™) coupled to an Orbitrap QExactive (Thermo Fisher Scientific™) 
tandem mass spectrometer. For identification, crosslinked peptides were 
separated on the nano HPLC by 180 minute gradients and analyzed by a data-
dependent approach acquiring CID MSMS spectra of the 10 most intense peaks 
(TOP 10), excluding single charged ions. The analysis was performed at the 
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Medical Proteome Center Tübingen (University of Tübingen). The raw data were 
directly analyzed with the MaxQuant software v1.5.2.8 (Cox and Mann, 2008). 
Downstream analysis was performed using Perseus v1.5.0.31 
(http://www.biochem.mpg.de/cox). 
3.13.3. Immunostaining 
To analyze cellular identification and distribution of specific proteins, 
immunostaining was utilized. This method employs the specificity of antibody-
antigen recognition. For plating, coverslips Ø 13mm, thickness I (Neolab) were 
placed inside wells (24-well format) and the different cell types were plated as 
described for them (see the respective cell type section). After the appropriated 
time of cultivation, cells were carefully washed in DPBS (PBS+/+), calcium, 
magnesium (Gibco™) and fixed with 300µL fixation solution (see Table 17) for 15
to 20 minutes at room temperature. After incubation time, fixation solution was 
discarded and cells were washed for three times in PBS+/+. In case of staining 
of an intracellular protein, non-ionic surfactant was used to permeabilize cells. 
Therefore 300µL Triton X -100 (Table 17) was added to cells, which were 
incubated at room temperature for more five minutes. Cells were once more 
washed in PBS+/+. To avoid unspecific binding of first antibody, 10% donkey or 
goat serum (Abcam) diluted in PBS+/+ was carefully given to cover cells surface 
and this was incubated at room temperature for 1 h. After blocking time, cells 
were incubated with first antibody solution for either 2h at RT or at 4°C, overnight. 
Dilution was done in blocking solution following supplier´s recommendation 
(Table 5). Before incubation with the second antibody, cells were washed in 
PBS+/+ for 5 minutes. Second antibody was diluted in PBS+/+, also according to 
supplier´s recommendation (Table 5). PBS+/+ was discarded and cells were 
incubated with second antibody solution at room temperature in dark for 1h. 
Finally, cells were washed for 3 minutes in PBS+/+, 3 more minutes in PBS and 
3 last minute in H2Odest. Water was discarded and the coverslip embedded in 
Prolong Gold with DAPI (Life Technologies) for nuclear staining. Coverslip was 
turned upside down on a slide 76 x 26 mm, extra white cutted with matt rim 
(Neolab). After drying in dark at room temperature, slides were kept at 4°C until 
microscopy. 
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Table 17. Solution employed for immunostaining 
 
Solution 
 
Composition 
Fixation 4% Paraformaldehyde (Carl Roth)  
10% Sucrose (Carl Roth) 
1X Dulbecco's phosphate-buffered saline no calcium, no 
magnesium (Gibco™)  
pH 7.4 (adjusted with 1M NaOH) 
Triton X -100  0.1% Triton X -100 (Carl Roth) diluted in DPBS, calcium, 
magnesium (Gibco™)  
All immunostaining pictures were acquired using Axio Imager M2 (Carl Zeiss - 
Oberkochen, Germany) microscope with a camera model Axiocam MRm (Carl 
Zeiss). Image was analyzed using the software provided by the microscope 
producer, Carl Zeiss AxioVision Rel. 4.7.2. 
3.14. Statistical methods 
3.14.1. Gene expression analysis  
Quantitative real-time PCR results were always normalized against the most 
suitable housekeeping gene. Statistical data charts always show the error bars 
for the standard error of the mean (S.E.M.). The sample size for control and 
patient hiPSCs is 6 each (3 different cell lines and 2 replicates each).  For other 
stages of neuronal differentiation (Days 5; 11 and 22), the sample size is 4 (2 
different cell lines and 2 replicates each). Statistical significance was determined 
by applying unpaired t-test and depicted by asterisk symbols, with the following 
meaning for the p-values: P≤0.001****; P≤0.01***; P≤0.03**; P≤0.05*; P≤0.1 (*). 
3.14.2. SILAC protein analysis 
As previously stated, peptides derived from SILAC experiment were identified by 
analysis of their mass spectrometry spectra. The analysis was performed at the 
Medical Proteome Center Tübingen (University of Tübingen).  
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Statistical analysis was performed using Perseus v1.5.0.31 
(http://www.biochem.mpg.de/cox). For this, unpaired t-test in combination with 
Significance B were simultaneously applied. This combination was thought to be 
more stringent, improving exclusion of false positives. Significance B determines 
outliers ratios based on normal distribution of median ratios.  
Only patient-control expression ratio values above 1.2 and below 0.83 were 
considered significantly different and presented. 
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4. Results 
4.1. Keratinocytes culture and generation of patient-derived iPS cell 
After informed consent was provided, hair-root samples containing an outer root 
sheath from two clinically diagnosed MEHMO patients were collect. The first 
affected individual (coded MH1) was a 5-years old child having a EIF2S3 
frameshift mutation (I465S fs*4), predicted to cause C-terminus truncation. The 
second donor (coded MH2) was a 15-years old patient, presenting a missense 
mutation (I222T) on the GTP-binding domain of eIF2S3. 
Keratinocytes, derived from the outer root sheath, were the somatic cell source 
of choice to be reprogrammed. Besides being originated from a tissue, which 
does not require invasive acquisition, keratinocytes are also simple to isolate and 
possess a high reprogramming efficiency (Raab et al., 2014). Therefore, hair 
samples from the two MEHMO patients were collect and keratinocytes were 
cultivated according to Aasen and Izpisua Belmonte, 2010 (Aasen and Izpisua 
Belmonte, 2010). 
Reprogramming (Figure 5) of these keratinocytes was successfully conducted 
using a multicistronic lentiviral vector carrying the four Yamanaka factors genes; 
namely: c-Myc, Oct4, Sox2 and Klf4 (Takahashi and Yamanaka, 2006). The 
reprogramming system still contained a fused red fluorescence marker that 
allowed the monitoring of exogenous Yamanaka factors expression and their 
posterior silencing, subsequent to pluripotency establishment (Warlich et al., 
2011). 
 
Figure 5. Scheme showing the different stages of keratinocytes reprogramming 
process. The first step shows hair roots plating and keratinocytes culture. This is followed 
by their reprogramming on a REF feeder layer, with formation of stem cell-like colonies 
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expressing Yamanaka factors (visualized also by the concomitant expression of red 
fluorescent marker). The later phase presents the induced pluripotent stem cell culture, in a 
feeder free system. 
In order to check whether protein localization changed with the mutation, 
immunostaining using control and patient keratinocytes/iPSCs was conducted 
(Figure 6). As expected, eIF2S3 protein is distributed all over the cell cytoplasm 
but also, in a less extended way, in the nucleus of keratinocytes. Although, no 
evident morphological difference was found between patient and control cells, 
and no nuclear eIF2S3 localization was observed in iPSCs from both groups. This 
raises the possibility of a nuclear role in certain cell types and/or cell cycle period 
that has not yet been described for this translation factor. 
 
Figure 6. eIF2S3 immunostaining of control and patient keratinocytes (40X objective) 
and iPS cells (63X objective). 
It has been shown though that other eukaryotic translation factors, such as 
eIF2S1, eIF4A and eIF4E can be highly localized in nucleus. eIF4E, for example, 
is responsible to increase cell cycle-related mRNAs export to the cytoplasm 
(Andersen et al., 2002; Culjkovic et al., 2007; Lobo et al., 1997; Tejada et al., 
2009). eIF2 subunits nuclear roles are therefore open to speculation, as their 
possible requirement in the still much debated process of nuclear translation 
(Bohnsack et al., 2002; Iborra et al., 2001).  
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4.2. Patient iPS cells characterization 
The generated human induced pluripotent stem cell (hiPSC) lines MH1, MH1C1 
and MH1C3 were characterized according to their pluripotency state and their 
capacity of differentiating into all three germ layers. Patient MH2 keratinocytes 
unfortunately did not undergo successful reprograming. All the other control cell 
lines generated for this study were equally evaluated (not shown here).  
4.2.1. Patient iPS cells pluripotency analysis 
As already mentioned in the introductory section, the pluripotency state of a cell 
is measured by its capacity of generating tissue from any cellular lineage when 
exposed to particular environmental cues. Moreover, stem cells possess a self-
renewal competence, being theoretically capable of infinite division cycles. 
In nature, stem cells exist temporarily and are formed during embryogenesis. 
Following maternal and paternal pronuclei fusion that gives rise to a totipotent 
zygote, the embryo undergoes a global DNA demethylation up to ICM formation 
(Guo et al., 2014; Smith et al., 2012). Cells at this stage have the so called naïve 
pluripotency identity, presenting a specific epigenetic landscape, which promotes 
expression of pluripotency genes and repression of those related to cell fate 
specification. 
As it is observed during embryogenesis, the epigenetic landscape is massively 
changed in the reprogramming process, and along with global transcriptional 
changes, it is an indispensable condition for pluripotency establishment. An 
intricate network for pluripotency maintenance is activated by a series of 
transcription factors (e.g. OCT4, NANOG and SOX2) known to have important 
downstream pluripotency targets. Therefore, standard analysis of gene 
expression were performed and endogenous OCT4, NANOG and SOX2
expression showed at least 20-fold increase in comparison to parental 
keratinocytes for the MH1 hiPSC line, as showed by Figure 7. 
The presence of the same transcription factors proteins was evaluated by 
immunostaining. They were all positive stained, along with other surface markers, 
known to be present in the membrane of pluripotent cells (Figure 8). 
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Figure 7. Pluripotency genes expression in MH1 hiPSC line. The graph shows the 
change in pluripotency gene expression level upon reprogramming. hiPSCs expression 
levels are compared to levels of parental keratinocytes cells. mRNA levels are relative to 
HMBS expression (Error bar is represented by S.E.M. of 3 technical replicates). 
 
 
Figure 8. Immunostaining of pluripotency markers for MH1 hiPSC colonies (10X 
objective). 
4.2.2. Differentiation of patient iPS cells into all three germ layers 
In order to assess if generated hiPSC lines were able to differentiate into the three 
germ layers, transcript levels of some important layers markers were analyzed by 
q-RT PCR (Figure 9). The analysis indicated a successful differentiation into all 
three embryonic germ layers, as represented by the highly expression of 
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endodermal (AFP and FOXA2), mesodermal (MYH6 and T) and ectoderm 
markers (PAX6 and TUBB3) when compared to undifferentiated hiPSCs.  
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Figure 9. Endoderm, mesoderm and ectoderm-related genes expression in MH1 three 
germ layer differentiation. The graph shows the ratio of gene expression levels in 
differentiated MH1 cells in comparison to MH1 hiPSCs (on logarithmic scale). mRNA levels 
are relative to HMBS expression. 
Besides gene expression, translation of SOX17 (endoderm), DESMIN 
(mesoderm) and TUBB3 (ectoderm) was verified by immunostaining, confirming 
cell line pluripotency (Figure 10). 
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Figure 10. Immunostaining of endodermal, mesodermal and ectodermal markers for 
MH1 three germ layer differentiation (20X objective). 
4.3. Gene expression analysis of patient derived iPSC lines 
In a first step evaluating patient specific alterations in gene expression patterns 
already at the iPSC state, we performed high-throughput qPCR to gain a global 
view on deregulated mRNA expression, investigating candidate genes related to 
the patient’s symptoms as well as genes related to eIF function.  
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Figure 11. Gene expression ratio between patient and control hiPSC lines. mRNA levels 
are relative to G6PD expression (P≤0.001****; P≤0.01***; P≤0.03**; P≤0.05*; P≤0.1 (*)). 
Notably, EIF2S3 gene expression was highly increased in patient hiPSCs along 
with the eIF2 β subunit (EIF2S2), while EIF2S1 presented no relevant change in 
expression. Moreover, two subunits of eIF2B, the guanine nucleotide exchange 
factor, which activates eIF2, were differentially expressed: EIF2B4 (δ subunit) and 
EIF2B5 (ε subunit). Still, among the eukaryotic translation initiation factors 
analyzed, eIF4G1, a member of the cap structure-guiding factor (eIF4F), 
presented a small increase in mRNA levels. 
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Figure 12. Gene expression ratio between patient and control hiPSC lines. mRNA levels 
are relative to G6PD expression (P≤0.001****; P≤0.01***; P≤0.03**; P≤0.05*; P≤0.1 (*)). 
Correlating with protein levels (Table 18), significant higher expression of APOE 
and CRABP1, as well as lower CBS expression was detected in patient iPSC 
lines. TKT, however, presented conflicting levels of protein and mRNA, in which 
patients had lower levels of protein and higher gene expression, when compared 
to control. Moreover, different retinoic acid-related genes, as well as genes 
associated to translation control, as ATF4 and MTOR were differently expressed 
in patients (Figure 12). 
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4.4. Generation of wild-type and mutated EIF2S3 overexpression HFF cell 
lines 
4.4.1. Creation of pLVX-TRE3G-4291 and pLVX-TRE3G-4292 
overexpression constructs 
To evaluate the effects that overexpression of EIF2S3 has on the expression of 
APOE, we developed two lentiviral plasmids (Figure 13 (b)). For this purpose, 
both pC4291 and pC4292 (Figure 13 (a)) (Borck et al., 2012) were object of 
cloning in a lentiviral system (Clontech Laboratories, Inc) based on co-
transduction of two vectors (Figure 13 (b) and (c)) that together can induce 
overexpression of the gene of interest (GOI). 
 
 
Figure 13. Schematic of the inducible expression system used and of the cloning 
strategy used to generate pLVX-TRE3G-4291 and pLVX-TRE3G-4292. (a) Gene of 
interest (GOI) was obtained by PCR from pC4291 and pC4292 templates using primers 
(D_Not_I_fw and D_NdeI_rev) that enabled the insertion of NotI and NdeI restriction sites in 
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the PCR products. Restriction of the amplified GOI´s generated the fragments A and B 
depicted. (b) Digestion of the multiple cloning site of pLVX-TRE3G using the same enzymes 
allowed GOI´s ligation downstream the inducible PTRE3G promoter. (c) Regulator plasmid 
is expressing Tet-On 3G transactivator protein, which undergoes a conformational change 
upon interaction with doxycycline, thus activating GOI expression.  
4.4.2. Gene and protein expression of HFF lines overexpressing WT and 
MUT EIF2S3  
Two different HFF lines were generated, one carrying the overexpression 
construct of EIF2S3 wild-type (WT), and another the mutated EIF2S3 form (MUT). 
Co-transduction of both the response and regulator derived viruses (sections 
3.5.1.2 and 4.4.1) with further selection of infected cells using puromycin and 
geneticin gave rise to the two HFF lines named OE-WT and OE-MUT. Moreover, 
a control cell line for the overexpression (CTRL) experiment was derived also by 
co-transduction of the viruses, but this time using a response plasmid lacking a 
GOI.  
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Figure 14. EIF2S3 and APOE gene expression in HFF lines overexpressing wild-type 
(OE-WT) and mutant (OE-MUT) EIF2S3 and in control HFF line (CTRL). The graph (left) 
shows EIF2S3 mRNA levels after 24 and 48h of doxycycline treatment and the right hand 
graph presents the increase in APOE expression when EIF2S3 mutant is overexpressed. 
mRNA levels are relative to GAPDH expression (Error bar is represented by S.E.M. of 3 
technical replicates; P≤0.001****; P≤0.01***; P≤0.03**; P≤0.05*; P≤0.1 (*)). 
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Figure 15. EIF2S3 and APOE protein levels in HFF lines overexpressing wild-type (OE-
WT) and mutant (OE-MUT) EIF2S3 and in control HFF line (CTRL). Western blot reveals 
eIF2S3 increased levels after 48h of DOX treatment and decreased levels of APOE protein 
after 24 and 48h of DOX treatment. All values are normalized to β-ACTIN levels. 
For induction of GOI expression, activation of PTRE3G promoter by Tet-On 3G 
transactivator protein were accomplished by treatment with doxycycline (DOX) 
for 24 and 48h. Cells were analyzed by q-RT-PCR and western blot. EIF2S3 
overexpression was successfully achieved at mRNA levels already after 24h of 
DOX treatment, and at protein levels increased only after 48h DOX treatment. On 
transcription levels, APOE is increased only when the mutated form of EIF2S3 is 
overexpressed, while APOE translation is down-regulated in all cases of 
overexpression, after 24 and 48h of DOX treatment (Figure 14 and Figure 15). 
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4.5. Generation of an HFF cell line with the inducible EIF2S3 knock-down 
system 
In order to investigate whether APOE up-regulation seen here for MEHMO 
patients could be correlated with a partial eIF2S3 loss of function, we employed 
a knock-down cell model (see section 3.7) by the use of a pTRIPZ lentiviral 
inducible shRNA expression vector (Open Biosystems). EIF2S3 silencing was 
induced by doxycycline (DOX) treatment for 1 to 8 days. The transduced cells 
expressing shRNA could be monitored by the concomitantly expression of a red 
fluorescent protein. 
4.5.1. Gene and protein expression of EIF2S3 knock-down in HFF cells 
Treatment with doxycycline (DOX) for up to 8 days induced transcription of 
shRNA, which successfully promoted EIF2S3 knock-down on mRNA and protein 
levels. Similar to EIF2S3, APOE expression decreased significantly upon EIF2S3
silencing. On the other hand, APOE protein levels did not correlate with gene 
expression and presented a biphasic regulation, in which after 1 day of DOX 
treatment its levels were decreased, while prolonged knock-down favored its 
translation (Figure 16 and Figure 17).  
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Figure 16. EIF2S3 and APOE gene expression in HFF control (CTRL) and EIF2S3 
knock-down (KD) lines after induction of shRNA expression using DOX for 1 to 8 days. 
The graph (left) shows the decrease in EIF2S3 mRNA levels after 1, 4 and 8 days of DOX 
treatment and the right hand graph presents the same effect on APOE expression upon 
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EIF2S3 silencing. mRNA levels are relative to GAPDH expression (Error bar is represented 
by S.E.M. of 3 technical replicates; P≤0.001****; P≤0.01***; P≤0.03**; P≤0.05*; P≤0.1 (*)). 
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Figure 17. EIF2S3 and APOE protein levels in HFF control (CTRL) and EIF2S3 knock-
down (KD) lines after induction of shRNA expression using DOX for 1 to 8 days. 
Western blot reveals successful EIF2S3 knock-down at protein levels already after 1 day of 
DOX treatment and a biphasic effect for APOE levels, in which decreased levels are observed 
after 1 day of DOX treatment and an increase after 4 days of treatment. All values are 
normalized to β-ACTIN levels. 
4.6. Stable isotope labelling by amino acid in culture (SILAC) of patient 
iPS cell lines 
Mutations in EIF2S3 were just recently found to be the genetic cause of MEHMO 
syndrome (G.Borck, personal communication). Besides a detailed phenotypic 
characterization of patients, nothing is known about the molecular basis of the 
disease. Therefore, a global protein analysis approach was chosen to guide our 
investigation into a more specific way, indicating proteins which have their 
translational rate affected by the mutation and, which could elucidate some of the 
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disease clinical features. 
The mentioned proteome- wide analysis, SILAC, employs culture of two different 
cell lines in distinct labelled amino acids media, and aims to compare the cell 
lines, with respect to their global translational rates. 
Figure 18 illustrates all the steps in a SILAC experiment, from cell culture in 
labelled amino acids media to mass spectrometry (MS) measurements. As 
previously described in section 3.13.2, patient-generated hiPSCs and healthy 
donor-generated hiPSCs were cultivated in SILAC medium supplied by normal 
light amino acids. Differences in protein turnover could be obtained by comparing 
the translational rate between patient and control samples, when medium was 
changed to labelled amino acids supplement media. 
 
 
Figure 18. Schematic diagram of SILAC experiment. Patient and control cells lines were 
fed with differently labelled amino acids (medium and heavy) and their derived proteins were 
mixed in a 1:1 ratio, digested and enriched for MS analysis. 
Two independent experiments were performed (Appendix B - Table B). In the first 
one the MH1C3 hiPS cell line was compared to the K5 hiPS cell line, while in the 
second the MH1C1 hiPS cell line was compared again to the K5 hiPS cell line. 
After MS analysis, data was calculated using both the MaxQuant software 
v1.5.2.8 (Cox and Mann 2008) and Perseus v1.5.0.31 
(http://www.biochem.mpg.de/cox). A combination of Student's t-test of the mean 
and Significance B was applied in both experiments. All the proteins overlapping 
in both experiments and of which ratio values were out of the methodological 
variation (Median: 0.83-1.2) were considered and all those that presented 
significant difference in translation (P≤0.05) are listed in Table 18.  
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Table 18. Proteins with deregulated translational rate in MEHMO patient-derived 
hiPSCs. Data summarizes results of two independent experiments. Each patient cell line 
indicated was compared with a control hiPS cell line. 
Gene Name Protein Name Patient iPSC 
line 
Median Comparison of 
protein levels 
APOE Apolipoprotein E MH1C1 1,609 Patient level higher 
than control 
MH1C3 1,768 
CRABP1 Cellular retinoic acid-
binding protein 1 
MH1C1 1,542 
MH1C3 1,499 
H2AFX H2A Histone Family Member 
X 
MH1C1 1,481 
MH1C3 1,465 
CBS Cystathionine beta-synthase MH1C1 0,498 Patient level lower 
than control 
MH1C3 0,409 
TKT Transketolase MH1C1 0,643 
MH1C3 0,564 
FABP5 Fatty acid-binding protein, 
epidermal 
MH1C1 0,812 
MH1C3 0,731
SLC2A3; 
SLC2A14 
Solute carrier family 2, 
facilitated glucose 
transporter member 3 and 
14 
MH1C1 0,563 
MH1C3 0,509 
SILAC is a very powerful mass spectrometry-based technique, which allows 
proteome comparison in a quantitative and global approach. The change of light 
to labelled amino acid medium permits the access of protein turnover. We cannot, 
however, determine specifically in which extend synthesis and degradation rate 
contribute to the final turnover rate measured with this procedure. 
To be able to compare control and patient cells, a slightly different method was 
chosen. In this procedure, control hiPSCs received medium labelled medium, and 
patient hiPSCs were fed with heavy labelled medium. At the end of the incubation 
time, a mixture containing 1:1 ratio of those samples was analyzed. The reverse 
labelling was also applied and analyzed, to exclude any effect that differently 
labelled amino acids could have on the results. 
Since eIF2S3 is, so far, not described to participate in any protein degradation 
process, the experimental design described above excludes any influence of 
differences in degradation rate. Being the degradation rates similar for control 
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and patient cells, the observed turnover was considered as a result of the 
difference in translational efficiency. 
Patient-derived iPSCs global protein analysis provided evidences for an 
imbalance in the translation of some interesting proteins, namely APOE, 
CRABP1, H2AFX, CBS, TKT and FABP5. Literature research indicates their 
association by direct and indirect means with two processes clearly affected in 
the patients: neurogenesis and adipogenesis. Moreover, diverse lines of evidence 
underscore their diverse role in survival/proliferative and apoptotic pathways. 
4.7. Differentiation of patient iPS cells into neurons 
Aiming to compare gene expression during early stages of neuronal 
development, control and patient iPSCs were subject of a neuronal undirected 
differentiation (Figure 19). Samples from four stages resembling singular
embryonic neurogenesis moments were collected, and expression pattern of 
genes that could be affected by EIF2S3 mutation were analyzed. 
The selection of genes was based on literature research and SILAC experiment 
results (Table 18). Besides, genes directly involved in initiation translation paths 
were selected, as well as pan-neuronal markers, which were used to show the 
successful differentiation of both control and patient cells. 
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Figure 19. Scheme illustrating the culture steps of neuronal undirected differentiation. 
Immunofluorescence analysis showing staining against OCT4 (Day0), Nestin (Day 10) and 
TUBB3 (Day 43) (20X objective). 
Primarily, no gross morphological differences were observed between control and 
patient lines in the different stages analyzed (Appendix – Figure A). Embryoid 
Bodies are hiPSCs aggregates that recapitulate, in vitro, the human pluripotent 
stage during embryogenesis, or blastocyst. Neural “rosettes” are epithelial cell 
structures possessing developmental parallel with the neural tube epithelium and 
a share very similar gene expression profiles. Neural stem cells (NSC) are 
multipotent cells capable of deriving as much neurons as glia cells and were 
present in the so called neurospheres. 
4.7.1. Gene expression analysis throughout patient neuronal differentiation 
To address the question of how the neuronal activity is impaired in the affected 
individuals, different stages of neuronal differentiation was analyzed via
expression of neuronal markers and other selected candidates that might be 
MEHMO relevant. As undirected neuronal differentiation protocols yield a very 
heterogeneous neuronal population, Day 43 of differentiation was only stained 
using the neuronal marker TUBB3 (Appendix A - Figure A). Although hiPSCs, or 
Day 0, was already addressed in section 4.3., the data is shown once more to 
give an overview of expression fluctuation over the differentiation process. Thus, 
Days 0, 5, 11 and 22 were chosen for gene expression analysis and pattern of 
expression of the different target genes are shown below. 
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The first set of genes (Figure 20) are those selected due to their close relation to 
eukaryotic translation initiation factor 2 and the translation initiation process itself. 
In addition to the already observed change in EIF2S2, EIF2S3, EIF2B4, EIF2B5 
and EIF4G1 expression on hiPSCs (Figure 11), no other significant discrepancy 
was detected during the course of neuronal differentiation, and all considered 
genes presented a very similar pattern of expression in both groups (patient and 
control). 
As already described, among the SILAC candidates analyzed, APOE, CRABP1 
and CBS hiPSCs mRNA levels confirmed the patient specific differentially 
expression that was seen in protein quantification (Table 18). Unlikely expected, 
patient TKT showed increased levels of mRNA. Besides that, CRABP1 and CBS 
exhibited same trend throughout neuronal differentiation significant at Day 5 of 
differentiation, for CRABP1, and at Day 11 for CBS expression (Figure 21). 
The third group of genes (Figure 22) covered MTOR, a master translation 
regulator and two genes known to directly control special neuronal mRNA 
translation - FMR1 and CYFIP1- (Figure 4). In addition, other genes which seem 
to be increased upon general translation suppression were selected, namely: 
PPP1R15A (Lee et al., 2009), PPP1R15B (Han et al., 2013), ATF4 (Vattem and 
Wek, 2004) and ATF5. The latter being chosen due to its role in regulating 
neuronal progenitors proliferation and differentiation (Greene et al., 2009). 
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Figure 20. eIF2S3-related gene expression in patient (green) and control (black) early 
neuronal differentiation. The graph shows expression levels of hiPSCs (Day 0); embryoid 
body (Day 5); neuronal “rosettes” (Day 11); neural stem cells (Day 22). mRNA levels are 
relative to G6PD expression (Error bar = S.E.M.; P≤0.001****; P≤0.01***; P≤0.03**; P≤0.05*; 
P≤0.1 (*)). 
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Figure 21. SILAC candidate gene expression in patient (green) and control (black) early 
neuronal differentiation. The graph shows expression levels of hiPSCs (Day 0); embryoid 
body (Day 5); neuronal “rosettes” (Day 11); neural stem cells (Day 22). mRNA levels are 
relative to G6PD expression (Error bar = S.E.M.; P≤0.001****; P≤0.01***; P≤0.03**; P≤0.05*; 
P≤0.1 (*)). 
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Figure 22. Other translation-related gene expression in patient (green) and control 
(black) early neuronal differentiation. The graph shows expression levels of hiPSCs (Day 
0); embryoid body (Day 5); neuronal “rosettes” (Day 11); neural stem cells (Day 22). mRNA 
levels are relative to G6PD expression (Error bar = S.E.M.; P≤0.001****; P≤0.01***; P≤0.03**; 
P≤0.05*; P≤0.1 (*)). 
Besides CRABP1 and FABP5, other genes related to different RA homeostasis 
and signaling aspects were investigated. Among the selected: PPARD, RARB, 
STRA6, RBP1, CYP26A1, RDH10 and LRAT were differently expressed in at 
least one moment of neuronal differentiation (Figure 23).  
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Figure 23. Retinoic acid-related gene expression in patient (green) and control (black) 
early neuronal differentiation. The graph shows expression levels of hiPSCs (Day 0); 
embryoid body (Day 5); neuronal “rosettes” (Day 11); neural stem cells (Day 22). mRNA 
levels are relative to G6PD expression (Error bar = S.E.M.; P≤0.001****; P≤0.01***; P≤0.03**; 
P≤0.05*; P≤0.1 (*)). 
Based on the actions of CRABP1 (non-canonical) could have on apoptotic 
pathways, apoptosis-related gene expression of DDIT3 and BCL2 was 
investigated, but no changes were observed along neuronal differentiation 
(Figure 24). 
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Figure 24. Apoptosis-related gene expression in patient (green) and control (black) 
early neuronal differentiation. The graph shows expression levels of hiPSCs (Day 0); 
embryoid body (Day 5); neuronal “rosettes” (Day 11); neural stem cells (Day 22). mRNA 
levels are relative to G6PD expression (Error bar = S.E.M.; P≤0.001****; P≤0.01***; P≤0.03**; 
P≤0.05*; P≤0.1 (*)). 
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Figure 25. Pan-neuronal markers gene expression in patient (green) and control 
(black) early neuronal differentiation. The graph shows expression levels of hiPSCs (Day 
0); embryoid body (Day 5); neuronal “rosettes” (Day 11); neural stem cells (Day 22). mRNA 
levels are relative to G6PD expression (Error bar = S.E.M.; P≤0.001****; P≤0.01***; P≤0.03**; 
P≤0.05*; P≤0.1 (*)). 
Finally, despite the absence of significant differences in most of the genes 
analyzed, it is possible to note that patient and control groups present, overall, a 
very similar trend of expression during the course of differentiation. Furthermore, 
similar patterns of neuronal marker expression- TUBB3 and PAX6 (Figure 25) 
indicates for the robustness of the differentiation protocol used.  
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5.  Discussion 
Although transcription and translation rates frequently correlate, higher 
expression of a particular gene does not necessarily mean subsequent and 
proportional increased functional protein synthesis (Vogel and Marcotte, 2012). 
Thus, it is relevant to emphasize that effective gene expression can be followed 
by reduced levels of the relative protein via different mechanisms, such as direct 
degradation of mRNA/protein, or even selective translation, favoring certain 
mRNA compositions. 
Aiming a more comprehensive view about how gene expression is affected in 
patients and to further assess whether SILAC candidate proteins (Table 18) 
presented comparable regulation on mRNA levels, RNA from patient and control 
iPS cells were extracted and analyzed by qRT-PCR (Figure 11 and Figure 12).  
Concerning EIF2S3 and EIF2S2 increase in expression in patient-derived iPSCs 
(Figure 11), it is noteworthy to mention that an overexpression of EIF2S2 in 
EIF2S3 mutated yeast restored cellular growth (Borck et al., 2012). This study 
also showed that human eIF2S3 is interacting with both eIF2S1 and eIF2S2, and 
that EIF2S3 mutation compromises eIF2S2 – eIF2S3 binding. Thus, an increase 
in EIF2S2 expression could compensate for this interaction inefficiency, also in 
human cells. Furthermore, both EIF2B4 (δ subunit) and EIF2B5 (ε subunit), also 
significantly increased in patient cells (Figure 11) are interacting with eIF2S2 
(Kimball et al., 1998) and the interface eIF2S2 –eIF2S3 contact with eIF2B5 has 
been reported as critical for the nucleotide exchanging role of eIF2B complex 
(Mohammad-Qureshi et al., 2007). By that line of reasoning, a slight increase in 
EIF4G1 could also be related to the improve of translational machinery efficiency, 
since eIF4G1 is participating in the activation of eIF4E and in the formation of 
eIF4F complex to bind the cap- structure (Shveygert et al., 2010). Moreover, 
EIF4G1 overexpression is associated to tumor progression, as its knock-down 
causes a decline in cell proliferation (Tu et al., 2010). 
Patient aberrant expression correlated with SILAC candidate genes APOE, 
CRABP1 and CBS, while TKT presented a significant inverse correlation (Figure 
12). Moreover, significant higher expression of genes correlated to cell response 
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to global translation rates (MTOR, PPP1R15B, ATF4) were detected along with 
an enhance in key genes of retinoic acid metabolism (STRA6, RDH10). 
Patient and control iPSC lines were subjected to an undirected neuronal 
differentiation. The continuously increasing expression of neuronal markers 
(Figure 25) indicates successful differentiation towards neuronal lineages. 
Besides this, all genes considered MEHMO-candidates were scrutinized along 
the differentiation process (section 4.7.1), and in the following sections their 
possible pathophysiological roles will be addressed. 
5.1. Eukaryotic translation initiation factor 2 subunit 3 and retinoic acid 
The patient significant and orchestrated increase in mRNA and protein levels of 
APOE and CRABP1 combined with lower FABP5 protein levels suggest a 
possible involvement of a common factor in the disease mechanism, namely
retinoic acid (RA). Intriguingly, extensive literature research provides numerous 
cases of neurodevelopment impairment attributed to deregulated RA metabolism 
(Berry et al., 2012; Berry and Noy, 2009; Berry et al., 2010; Choi et al., 2014; 
Cohen et al., 1999; Corcoran et al., 2002; Huang et al., 2011; Jacobs et al., 2006; 
Krezel et al., 1998; Latasa and Cosgaya, 2011; Olson and Mello, 2010; Sandell 
et al., 2007; Shenefelt, 1972; Yu et al., 2012). The tightly regulated cellular 
response to RA gives a hint about the importance of such signaling, and lack of 
some important RA metabolic enzymes, receptors, or transporter proteins could 
irretrievably affect RA physiological homeostasis. How EIF2S3 mutation favors 
translation of those proteins and whether RA is in center of this process remains 
unknown. 
5.1.1. Cellular retinoic acid binding proteins 
The control of the intracellular concentrations of RA is regulated at several levels 
of its metabolism. Vitamin A, the RA precursor, is mainly stored in the liver as 
retinyl esters, which are metabolized by hepatic enzymes to retinol and 
transported via blood stream bound to RBP4. Retinol is internalized by cells and 
further metabolized to RA in a process involving several enzymes and transporter 
proteins. Besides, reversible catalysis in RA synthesis, the control of gene 
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expression and generation of RA metabolites are of extreme importance in 
regulating cytoplasmic and nuclear RA levels.  
Among the regulatory systems, maintenance of plasma steady levels is possibly 
the most relevant, since changes in vitamin A intake affect mainly hepatic retinyl 
esters storage, while retinol levels are maintained steady, allowing therefore a 
constant concentration of cellular available RA (Batres and Olson, 1987). 
A special class of binding proteins, the cellular retinoic acid binding proteins 
(CRABP) belong to the very last steps of RA metabolism in the cytoplasm. 
CRABP proteins are essential in RA signaling pathways, but despite their shared 
RA binding feature and their common role in diminishing cytoplasmic 
concentration of RA, CRABP family members (CRABP1 and CRABP2) present 
singularities that have been studied in the past decades.  
The aforementioned decrease in RA cytoplasmic levels by CRABP proteins is 
caused via two different mechanisms: transport into the nucleus by CRABP2, 
activating diverse receptors, or catabolism, due to the action of two proteins, the 
enzyme CYP26 (Hernandez et al., 2007) and the carrier CRABP1 (Won et al., 
2004). 
CRABP1 (Canonical role) 
Although no activation of retinoid receptors (RARs and RXRs) by direct function 
of CRABP1 has been reported (Venepally et al., 1996), its role in controlling RA 
intracellular concentrations has been shown (Napoli, 1993; Wei et al., 1999). 
Others also demonstrated a direct correlation of higher CRABP1 expression and 
higher levels of RA metabolites in carcinoma cells (Boylan and Gudas, 1992; Won 
et al., 2004). In accordance with the idea that CRABP1 is controlling cytoplasmic 
concentrations of RA, and therefore the amounts of available nuclear RA, 
CRABP1 overexpression produced a reduced cellular response to RA in F9 stem 
cells and head carcinoma (Boylan and Gudas, 1991; Won et al., 2004). To assess 
whether CRABP1 is also able to facilitate RA signaling, Wei and colleagues (Wei 
et al., 1999) generated lower RA-affinity CRABP1 to compare with the wild type 
protein. The experiment detected a biphasic effect of CRABP1, in which higher 
levels of wild type CRABP1 would increase RA nuclear receptor induction in a 
first phase, while in a posterior moment a decrease in this induction was reported. 
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This report raised the question whether CRABP1 would have other functions 
aside from mediating RA catabolism. 
RA roles in stem cell fate was investigated and, differently from F9 cell line, which 
is induced by RA to form endodermal tissue (Strickland and Mahdavi, 1978), 
exposure of P19 to RA resulted in different cell types, including some of neuronal 
origin (Kanungo, 2016). Thus, the sensitivity to RA seems to differ among cell 
types. Also contrarily to F9, P19 presents augment of CRABP1 levels following 
RA treatment (Means et al., 2000), illustrating again CRABP1 function in 
regulating RA nuclear levels. 
Since RA bound to CRABP1 has a more significant increase in catabolism than 
free-RA (Napoli, 1993), cells expressing this binding protein might do so, as a 
protection measurement in order to bring RA levels to physiological 
concentrations. Taking this into consideration, it is possible that higher levels of 
CRABP1 in patient iPSCs (Figure 12 and Table 18) is causing a slight 
deregulation on retinoid levels, as other genes related to increase of cellular RA 
precursors levels were up-regulated in patient (Figure 12). Therefore deregulated 
levels of RA, due to increased CRABP1, could produce deleterious effects during 
patient early development, as e.g. STRA6, a cellular retinol uptake protein is 
maintained elevated along neuronal differentiation (Figure 23). 
A possible CRABP1 role in neurogenesis is supported by the unquestionable RA 
activity in neuronal development (Janesick et al., 2015), and by the observation 
that both CRABP1 and CRABP2 transcripts distribution in embryogenesis 
exhibited a strong increase in expression during neural crest cells migration and 
in neural epithelium in mice (Leonard et al., 1995; Ruberte et al., 1991). 
Therefore, the neurodevelopmental aspect of MEHMO syndrome reveals that 
CRABP1 might be an interesting study target to unveil unexplored paths of 
neurogenesis. 
Despite CRABP1 and CRABP2 being highly conserved, both CRABP1- and 
CRABP1/CRABP2 null mutant mice did not present overt malformations (Gorry 
et al., 1994; Lampron et al., 1995). However, it is important to note that besides 
the difficulties in evaluating mouse phenotype, which are sometimes only evident 
under special conditions, the absence of several genes can be compensated in 
some species, while are disease causative, or even lethal in others (Barbaric et 
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al., 2007). Furthermore, a severe intellectual disability syndrome in the CRABP1 
chromosomal region (15q24) was reported in members of a consanguinity 
Pakistani family (Mitchell et al., 1998) which seems to inherit the condition in a 
recessive manner. Finally, differently from null mutations where the protein, if 
present, does not accomplish its function, gene overexpression may result in a 
completely different phenotype. In contrast to the previously mentioned absence 
of phenotype in CRABP1 null mice, and resembling what is observed in patients 
regarding enhanced CRABP1 expression, a transgenic mice overexpressing 
bovine CRABP1 produced only sterile female offspring that presented severe 
development phenotype in a variety of organs where the protein was expressed 
(Wei et al., 1992). 
CRABP1 (Non-canonical role) 
Apart from CRABP1 canonical function, a very recent role has been described for 
this molecule, in which its intriguing association to protein synthesis is noticeable. 
Instead of controlling intracellular levels of RA, via RA delivery to catalytic 
enzymes from cytochrome P-450 family, CRABP1 was shown to exhibit an 
ERK1/2 phosphorylation activity via binding of RA when examining embryonic 
stem cells (Persaud et al., 2016). With a high level of complexity, ERK1/2 
signaling possesses opposing effects depending on its localization and strength 
of activation signal (Wortzel and Seger, 2011), so it can act promoting both 
proliferative and apoptotic responses. During CRABP1-mediated ERK1/2 
phosphorylation, an increase in Bax/Bcl-2 protein ratio was observed, resulting in 
an apoptotic increment, also perceived by the growth of protein phosphatase 2A 
(PP2A) activity, a tumor suppressor protein.  
Knowing that PP2A negatively regulates eIF4E phosphorylation (Li et al., 2010b), 
an activation of PP2A would ultimately produce a decrease in cap-dependent 
translation initiation. In this scenario, MEHMO patient cells translation would 
certainly be aggravated.  
Cells exposed to extreme situations require an immediate response, as for 
example due to nutrient deprivation. Thus, it is natural to assume that translation 
might be coupled with apoptotic mechanisms, responding to sudden changes in 
cell physiology. In fact, diverse translation inhibitors have been long associated 
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to cell death by activation of Bcl-2 family apoptotic pathways (Lindqvist et al., 
2012; Narayanan et al., 2005). Thus, a global translation decrease, as 
hypothesized here for MEHMO syndrome, is likely leading to activation of 
apoptotic pathways, which are not necessarily executed, since the apoptosis-
triggering signal could be counterbalanced by other regulatory mechanisms, 
considering that even late stage apoptosis can be reversible (Tang et al., 2012). 
Thereupon, future apoptosis assay would be interesting to assess whether 
patient cells are prone to suffer apoptosis, due to CRABP1 higher levels of 
expression. A slight glance on it was done through the analysis of two apoptosis-
related gene expression (BCL2 and DDIT3). Although patient BCL2 and DDIT3 
(CHOP) mRNA levels were comparable to control in all stages (Figure 24), it 
would be interesting to check for protein levels, since CRABP1 was described to 
decrease protein levels of BCL2, while its transcription was unaffected (Persaud 
et al., 2016).  
Finally, it is possible that CRABP1/RA exerts particular roles in different tissues 
and/or embryo development stages, as CRABP1 was reported to have two 
enhancers, one upstream of the gene, regulating its expression in the neural 
region, and another one responsible for mesenchymal and neural crest 
expression, located downstream from exon II (Kleinjan et al., 1997). Studies in 
different cancer cells produced conflicting data. Tanaka et al. (Tanaka et al., 2007) 
found the gene to be silenced in carcinoma cells and restoration of its expression 
led to a decrease in growth, by inducing cell cycle arrest. The gene knock-down, 
on the other hand, induced the opposite effect, supporting CRABP1 non-
canonical role. Contrarily, the gene was found to be up-regulated in ovarian 
cancer (Banz et al., 2010) and responsible for increasing metastatic activity in 
mesenchymal and neuroendocrine tumors (Kainov et al., 2014). 
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Figure 26. Simplified schema of CRABP1 roles demonstrating the activation of retinoic 
acid (RA) catabolic reaction (canonical) and the mediation of apoptosis via ERK1/2 
phosphorylation (non-canonical) by binding of RA.  
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5.1.2. CRABP2 and FABP5 (Lipid binding proteins) 
Both cellular retinoic acid binding protein 2 (CRABP2) and fatty acid binding 
protein type 5 (FABP5) are lipid binding proteins known to present RA to specific 
nuclear receptors, enabling the regulation of distinct cohort of target genes. Thus, 
according to the abundances of these molecules RA can mediate different effects. 
A sophisticated control mechanism of cell apoptosis and survival was proposed 
when investigating the targeting of different nuclear receptors by RA in skin tissue 
(Schug et al., 2007). In contrast to the catabolic effects caused by RA activation 
of retinoic acid receptors (RAR), the activation of peroxisome proliferator-
activated receptor β/δ (PPARβ/δ) by RA produces an anti-apoptotic cellular 
response. The RA receptor selection was described as depending on the balance 
of the two early mentioned RA delivery proteins, CRABP2 and FABP5. These 
transporter proteins have the ability to bind RA and deliver it specifically to RAR 
and PPARβ/δ, respectively. Thereby, being CRABP2/FABP5 ratio high, RAR 
activation path is favored, while a low ratio supports PPARβ/δ activation and 
therefore, anti-apoptotic effects. A binding assay still revealed that the association 
of RA to CRABP2/RAR in comparison to FABP5/PPARβ/δ is higher in most cells, 
meaning that for a relevant PPARβ/δ activation to occur, a low CRABP2/FABP5 
is needed (Schug et al., 2007).  
In addition to its anabolic effect on skin, FABP5 was reported as an essential 
factor on neurite growth (Allen et al., 2000). Analysis of rat FABP5 (E-FABP) 
mRNA and protein expression patterns showed high expression levels during the 
whole process of brain development (Liu et al., 2000). Recent work associated 
FABP5 and CRABP2 with RA signaling in neurogenesis by investigating their 
expression pattern and correspondent pathways activation throughout neuronal 
differentiation (Yu et al., 2012). 
Furthermore, PPARβ/δ is the most abundant isotype expressed during nervous 
system development (Braissant et al., 1996). Its in vitro selective activation 
caused significant increase in late maturation of mice oligodendrocytes, produced 
anti-apoptotic effects (Saluja et al., 2001) and, along with FABP5, PPARβ/δ 
seems to be important for neurite outgrowth (Benedetti et al., 2015).  
Although not highly significant, our control group presented a constant increase 
in PPARβ/δ expression throughout neuronal differentiation, while patient cells 
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showed a relatively constant low expression (Figure 23). In this regard, it is worth 
mentioning that down-regulation of FABP5 reduced PPARβ/δ expression (Yu et 
al., 2012), and that MEHMO FABP5 protein levels were lower in comparison to 
control cells, at least at the hiPSCs stage. However, it remains elusive whether 
or not the patient low levels of FABP5 protein is maintained throughout neuronal 
development. 
 
 
Figure 27. Retinoic acid (RA) activation and repression roles in neuronal differentiation 
gene regulatory network. Balance between RA-binding proteins CRABP2 and FABP5 
determine to which nuclear receptor (RAR and PPARβ/δ, respectively) RA is being delivered. 
CRABP2/FABP5 ratio is therefore determining whether to induce neuronal progenitor 
formation or neuronal maturation. The two highlighted boxes might be under-activated in 
MEHMO patients, when FABP5 protein are kept under normal levels, in comparison to 
CRABP2. 
Based on Yu et al., 2012, the scheme above (Figure 27) shows the effects caused 
by RA delivery and activation of RAR and PPARβ/δ in different time points of 
neuronal differentiation. Similarly to CRABP2, a transient up-regulation of RARβ 
is also observed during the early phase of neurogenesis, and this effect was also 
observed in the course of our differentiation (Figure 23).  
A mechanism to control differentiation rate is operating by the increase of 
FABP5/CRABP2 ratio, which impairs neuronal progenitor formation and 
consequently neurogenesis. In a late phase of the differentiation process the 
down-regulation of CRABP2 is stimulating neuronal maturation, by allowing 
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FABP5 induction of PDK1 expression, a gene which promotes neuronal 
maturation. Interestingly, FABP5 knock-out mice displayed expansion of 
progenitor markers, while presenting lower levels of mature neurons in 
comparison to wild-type mice (Yu et al., 2012). Thus, in case the correspondent 
FABP5 protein deficiency in MEHMO patient iPSCs is maintained throughout 
development, the two highlighted steps (Figure 27) might be kept suppressed 
during patient neuronal differentiation, causing CRABP2/FABP5 ratio imbalance 
with expected increase in patients neuronal progenitors population and poor 
maturation.  
Finally, we found it interesting that RARβ presented higher expression levels in 
patient (Figure 23). This could also characterize an increased number of 
progenitors, fitting to the elevated levels of PAX6 at the same stage of 
differentiation - Day 11 - (Figure 25), once PAX6 is known for promoting neural 
stem cell self-renewal in a dose-dependent way (Sansom et al., 2009). 
Anandamide signaling 
Another pathway stimulating neurogenesis and, in which FABP5 could be 
involved with, is that of anandamide. Anandamide was first identified as a 
cannabinoid receptor agonist in porcine brain (Devane et al., 1992) and its 
metabolites (ethanolamine and arachnoid acid) were described as hydrolytic 
degradation products (Di Marzo et al., 1994). Findings on anandamide carriers, 
namely FABP5 and FABP7, explained how the molecule is able to move within 
the hydrophilic cytosol, since it is presenting a lipophilic character. In addition to 
transport anandamide, the carries were found to increase the hydrolysis rate of 
the molecule (Kaczocha et al., 2009). 
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Figure 28. Anandamine signaling highlighting the action of FABP5 transport protein in 
anandamine metabolism and cognition associated genes activation, via delivery of 
arachidonic acid to PPARβ/δ nuclear receptor. Legend: ANA: Anandamine; FABP5: Fatty 
Acid-Binding Protein 5; FAAH: Fatty Acid Amide Hydrolase; AA: Arachidonic Acid; PPARβ/δ: 
Peroxisome Proliferator-Activated Receptor; PPRE: PPRA responsive element. (Adapted 
from (Yu et al., 2014)). 
Besides activating cannabinoid receptors itself, anandamide metabolic product, 
arachnoid acid, presents an agonistic activity in relation to PPARβ/δ nuclear 
receptor in brain, up-regulating cognition associated genes (Yu et al., 2014). 
FABP5 transporter directly delivers arachnoid acid to PPARβ/δ nuclear receptor, 
being ultimately responsible for regulation of receptor activity, and consequently 
its cognition associated target genes expression (Yu, et al., 2014). Furthermore, 
the transcriptome of a cell line expressing high levels of FABP5 and treated with 
a selective PPARβ/δ agonist generated a list of possible target up-regulated 
genes, many of those involved in neuronal functions, including learning and 
memory processes (Yu et al., 2014) (Figure 28).
Thus, being FABP5 decreased in patient-derived iPSCs (Table 18), and PPARβ/δ 
expression reduced during neurogenesis (Figure 23), the maintenance of lower 
levels of these factors in mature neurons may compromise regulatory 
downstream process. 
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5.1.3. Apolipoprotein E, retinoic acid and lipids metabolism 
Apolipoprotein E (APOE) functions as a binding protein carrying hydrophobic 
molecules, such as cholesterol and retinyl esters, throughout the circulatory 
system. Being a ligand of membrane receptors, such as low density lipoprotein 
receptor (Havel, 1998), APOE mediates uptake of chylomicron remnants and 
other lipoprotein particles by hepatocytes and regulates their traffic in diverse 
tissues.  
Nervous system  
Cholesterol, essential for membrane integrity, myelin production and proper 
neuronal development, is highly enriched in brain, where its binding protein APOE 
is also greatly expressed. Thus, it is logical to assume that APOE plays a role in 
cholesterol homeostasis, and that disruptions in this homeostasis caused by 
APOE could affect brain health and development (Dietschy, 2009). Therefore, 
APOE has been subject to extensive analysis and its different isoforms proved to 
influence the onset and progress of cardiac, Alzheimer´s and other neurological 
diseases in different ways (Mahley, 2016). 
Along with cholesterol, RA is a fundamental substance for brain development and 
its precursor is likewise transported by APOE. Exclusively obtained via diet, 
vitamin A is absorbed as retinyl esters in the intestinal mucosa and incorporated 
into chylomicron remnants, which also consist of APOE. APOE mediates 
chylomicron remnants uptake in hepatocytes and retinyl esters are stored in its 
major storage, the stellate cells. As RA precursors cannot be synthetized, their 
uptake and transfer is of utmost importance to life (D'Ambrosio et al., 2011). 
As earlier noted, APOE high expression in brain, mostly in glia cells, is long known 
(Boyles et al., 1985). The development of a transgenic mice expressing 
fluorescent tag enabled a sensitive description of APOE pattern of expression in 
CNS, and detected hippocampal neurons expression upon injury, in addition to 
high expression in cells belonging to choroid plexus and smooth muscle from the 
CNS vessels (Xu et al., 2006). 
Membrane composition and other associated features, as fluidity and 
permeability are highly influenced by the amount of cholesterol. In brain, this 
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essential component is mainly glial-derived and, as before mentioned, 
transported by APOE. Notably, cholesterol and APOE are playing a role in 
synaptic maturation and activity (Dietschy, 2009; Mauch et al., 2001; Oh et al., 
2010). Regardless of numerous studies indicating the negative influence of 
APOE4 isoform on spine formation and dendritic complexity (Dumanis et al., 
2013; Dumanis et al., 2009; Jain et al., 2013; Ji et al., 2003; Klein et al., 2010; 
Nwabuisi-Heath et al., 2014; Rodriguez et al., 2013), a report of APOE absence 
in patient questions whether lack of APOE could have any neurological effect, 
since excepting dyslipidemia, patient presented no obvious CNS abnormality. 
Normal neurogenesis might indicate that another mechanism could replace the 
role of APOE during development, but as also highlighted by the authors, a 
progressive neurodegeneration is not excluded, and therefore a patient follow up 
is imperative (Mak et al., 2014). 
In addition to membrane composition, equally important is the role of cholesterol 
in myelin production, where it is required in higher concentrations (Saher et al., 
2005). Herein, the demonstrated up-regulation of APOE upon neuron injury is 
also interesting, since APOE is believed to assist myelin production following 
injury by increasing myelin debris clearance and Schwann cholesterol uptake in 
the PNS (Fagan et al., 1998; Goodrum, 1991; Li et al., 2010a). Besides that, 
APOE polymorphism is associated to differences in myelin content (Bartzokis et 
al., 2006; Dean et al., 2014). 
Due to its interesting roles in the homeostasis of both retinoic acid and 
cholesterol, APOE expression has been widely studied. The gene presents 
multiple and complex regulatory elements, that can be specialized for different 
tissues. Several transcription factors, including nuclear receptors have been 
unveiled, but a lot of specificities are still uncovered (Allan et al., 1995; Berg et 
al., 1995; Garcia et al., 1996; Grehan et al., 2001; Liang et al., 2004; Paik et al., 
1988; Shih et al., 2000; Smith et al., 1988; Yue and Mazzone, 2009; Yue et al., 
2004; Zhao et al., 2014a; Zheng et al., 2004).  
Different studies identified APOE among RA responsive genes, when analyzing 
both neural stem cells and astrocytes cultures (Cedazo-Minguez et al., 2001; 
Jacobs et al., 2006; Zhao et al., 2014a). Additionally, a neuronal specific 
cholesterol metabolite induced astrocytes APOE protein synthesis in a dose-
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dependent manner, suggesting a link between neuronal metabolism and glial 
cholesterol supply that could perfectly influence neuronal synaptic plasticity 
(Abildayeva et al., 2006). But, as observed by Göritz and colleagues, an 
exorbitant secretion of APOE could deplete the cholesterol availability, impairing 
both synaptic function and nerve regeneration (Goritz et al., 2002). 
Considering the apparent lack of phenotype in the absence of APOE, the gene 
induction upon brain injury, and the different synaptic plasticity modelling caused 
by each APOE isoform, we could hypothesize that more than its absence, APOE 
abnormal up-regulation could bring deleterious developmental and neuronal 
effects.  
As mentioned earlier, APOE can have tissue-specialized regulatory elements, 
thus it is difficult to know how APOE protein levels are being controlled along 
differentiation. In one hand, it could be that the lack of differential expression 
between patient and control during neuronal differentiation (Figure 21) reflects 
what is also seen at protein level in these stages. On the other hand, an 
uncoupled transcription and translation control of APOE levels could take place 
and, as consequence, APOE protein could be increased during patient 
neurogenesis, as a result of a preferred translation mechanism, for example. 
As delayed myelination and ataxia gait can be found on MEHMO patients, it would 
be interesting to investigate the effects that up-regulation of APOE, in its three 
genotypes, could have on white matter formation, by examining myelinating 
oligodendrocytes and Schwann cells differentiation. 
To conclude, a direct link between APOE and translational mechanism in neurons 
is presented by Segev and colleagues in two studies where they observed human 
APOE4 inducing growth of eIF2S1 phosphorylation rates in mice brain and also 
increasing levels of ATF4, when compared with APOE3 (Segev et al., 2015; 
Segev et al., 2013). 
Cardiovascular system and obesity 
Apart from patient neurological dysfunction, obesity, diabetes and dyslipidemia 
might be considered in the context of patient iPSCs high levels of APOE (Figure 
12 and Table 18). 
Interestingly, besides development of hypercholesterolemia, APOE -/- mice 
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hallmarks are their lower propensity to gain weight and smaller adipocytes, 
probably due to their inability to take up fat via APOE. APOE adipogenic induction 
was long addressed in mice and human studies demonstrating a specific role of 
APOE in internalization of lipoproteins and differentiation of preadipocytes (Chiba 
et al., 2003; Huang et al., 2006; Lasrich et al., 2015). Although Chiba et al. 2003 
showed an increase in adipogenesis via APOE bound to VLDL, Huang et al., 2006 
questioned this finding, showing that adipocytes devoid of APOE are unable to 
increase their lipid content in presence of APOE bound to lipoproteins. In order to 
investigate a possible and specific role that adipocyte APOE expression could 
have on adipogenesis and obesity development, a tissue-target experiment 
model was applied and revealed that adipose tissue APOE deficiency was not 
sufficient to reduce lipid content and avoid adipogenesis (Wagner et al., 2015), 
demonstrating that other APOE sources, rather than adipocyte expressing cells, 
might compensate this lack of tissue endogenous APOE expression. 
Besides APOE fat accumulation role, investigations on glucose metabolism 
indicated that lack of APOE improve glucose tolerance and insulin sensitivity 
(Gao et al., 2007; Hofmann et al., 2008; Karagiannides et al., 2008). 
In line with these observations, mouse expressing human APOE became obese 
and exhibited hyperglycemia and glucose intolerance (Karagiannides et al., 
2008). Additionally, overexpression of human APOE in mice and rabbits resulted 
in increased plasma levels of cholesterol and triglycerides (Huang et al., 1999; 
Huang et al., 1998). This could indicate a stronger predisposition of human APOE 
to induce these symptoms in comparison to its rat orthologue (Shimano et al., 
1992; Yamamoto et al., 1995), and that APOE effects are highly dose-dependent, 
as also demonstrated by Huang and colleagues (Huang et al., 1998). 
Unexpectedly, however, results from an investigation on APOE overexpression 
showed that high levels of APOE expression in human adipocytes was not 
correlated to increase in cell lipid accumulation. In spite of that, the aberrant 
overexpression, producing large amounts of APOE, converted adipocytes into 
cells more resistant to serum deprivation and increased their proliferative capacity 
(Carmel et al., 2009). This acquired cell characteristic could be examined from 
the perspective of translation impairment in MEHMO syndrome, in which a 
mutation in a key translation machinery factor leads to APOE increased 
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transcription and translation. Furthermore, nutrition/serum deprivation was 
associated to increase in APOE levels in different cell types (Do Carmo et al., 
2002; Huang et al., 2007), showing again a correlation between decreased 
translation cell state and higher amounts of APOE. Added to starvation-induced 
growth arrest, apoptosis activation also promoted APOE up-regulation in mRNA 
and protein levels (Quinn et al., 2004). 
In line with all these evidences, ovarian, breast and prostate cancer cells studies 
revealed an overexpression APOE, while APOE increased plasma 
concentrations was shown to associate with metastasis in lung cancer patients 
(Chen et al., 2005; Luo et al., 2016; Papi et al., 2012; Venanzoni et al., 2003). 
Thus, it is tempting to speculate that the APOE increment observed in MEHMO 
patient could be a coping mechanism to increase cell division capacity, against 
the translation impairment imposed by EIF2S3 mutation. Herein, it is also 
interesting to consider APOE previously mentioned role in acting upon brain 
injury. This could be another indication of a cell response connecting APOE to 
translation. Whether neurons may activate pro-survival pathways via APOE 
expression, and whether APOE isoforms and dose-dependence play relevant 
roles remain open questions.  
Also regarding MEHMO patient phenotype, it is plausible to question whether 
hyperglycemia, dyslipidemia and obesity observed are correlated to the detected 
higher APOE levels, and whether an increase in cell proliferation during 
adipogenesis is the major contributor for obesity, being hypertrophy of adipocytes 
a less prominent factor. 
Still in agreement with the idea of APOE being related to translation and, as seen 
for APOE4 genotype in brain (Segev et al., 2015; Segev et al., 2013), APOE 
deficient lipoproteins were also shown to induce phosphorylation of eIF2S1, 
decrease global translation and up-regulate ATF4 in macrophages (Wu et al., 
2008). This difference in APOE isoforms could be one of the reasons why 
MEHMO syndrome displays variable expressivity. Therefore, it would be 
interesting to investigate which APOE alleles patient and control individuals 
inherited. 
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Figure 29. Summary schema of APOE expression inducers and the postulated 
consequences of APOE expression. 
EIF2S3 misexpression and APOE 
We could observe a successful overexpression of EIF2S3 already after 24h of 
DOX treatment; however, a correlation with protein increase was detected after 
48h DOX treatment, with higher levels of WT protein being translated in 
comparison to the mutated form (Figure 14 and Figure 15). Between transcription 
and translation of a gene, there are multiple levels of regulation, which will 
ultimately determine whether or not these two processes are coordinated. Among 
these regulatory mechanisms, mRNA and protein stability could perfectly differ 
between WT and MUT forms. Another point to be considered is that eIF2S3 is 
itself part of a protein complex, directly controlling translation initiation and 
therefore, its mutation might implicate in differential protein translation of mRNA 
strictly dependent on ternary complexes, including its own synthesis. APOE 
transcription was only increased upon overexpression of the MUT EIF2S3 (Figure 
14). This interesting effect resembles what is seen in MEHMO patient, once the 
patient eIF2S3 is causing enhanced levels of APOE transcripts. Nonetheless, the 
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expected increase in protein levels, such as observed in patient cells, was not 
apparent, at least not after 48h overexpression. On the contrary, the opposite 
response was seen, in which lower levels of APOE protein could be detected after 
24 and 48h of DOX treatment. This very complex scenario can have different 
explanations. Firstly, overexpression is an artificial mean of studying dose-
dependent cell response and it may disrupt other cellular processes producing 
unpredictable phenotypes. In the case studied here, EIF2S3 overexpression 
might disturb the stoichiometry of eIF2 complex formation and consequently 
translational controlling mechanisms that cannot be traced. Another possibility is 
that unphysiological higher levels of eIF2S3 could activated new, previously non-
related pathways. Very intriguing, and still open is the fact that even before 
eIF2S3 protein overexpression can be detected, changes in APOE transcription 
and translation are already observed (Prelich, 2012). 
Whether this down-regulation in APOE translation is a direct cause of an increase 
in translation efficiency and whether MUT eIF2S3 cannot compete with the 
endogenous protein are still to be unveiled. We could, nevertheless, hypothesize 
that an increase in ternary complexes availability, even when not fully functional, 
as in the case of MUT eIF2S3, is repressing APOE translation. Insofar as, 
diminished levels of eIF2S3, produced by the gene knock-down, presented the 
exact opposite effect on APOE mRNA and protein levels (Figure 16 and Figure 
17), when compared to the MUT overexpression experiment. Thus, corroborating 
with what discussed in the previous section, the continuous down-regulation of 
eIF2S3, such as in cases of nutrient starvation and apoptosis, resulted in 
increased APOE protein levels. 
To conclude, differently from overexpression, which intends to disclose how the 
mutation itself is changing phenotype, the gene silencing experiment aimed to 
functionally characterize the endogenous gene by causing a reduction of its 
abundance. Even though these assays do not represent a faithful copy of the 
MEHMO pathology mechanism, they seek to unveil a possible dose-dependence 
relation between APOE and eIF2S3. 
5.1.4. Other RA-related molecules 
Considering the vast spectrum of RA activities in coordinating diverse 
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developmental process, and the indication of a possible deregulation RA levels 
in patients, some other RA-related molecules were chosen for mRNA levels 
measurement during early neuronal differentiation. These genes encode binding 
proteins (CRABP2, FABP4, FABP5, RBP1), a cellular retinol uptake protein 
(STRA6), nuclear receptors (RXRA, RARB, NR1H3, PPARβ/δ), a storage-related 
enzyme (LRAT), RA-synthesis enzymes (RDH10, RALDH2) and a RA-catabolic 
enzyme (CYP26A1). 
Among those genes, CRABP2, FABP4, FABP5, RXRA, NR1H3 and RALDH2 did 
not show any significant difference in expression between control and patient 
groups when analyzing all stages of differentiation (Figure 21 and Figure 23).  
A decrease in patient cytochrome P450 Family 26 Subfamily A Member 1 
(CYP26A1) mRNA levels was observed at Day 22 of differentiation (Figure 23). 
This CYP26 family member is important in early stages of development and has 
been found to be in a negative feedback fashion up regulated by RA (Ross and 
Zolfaghari, 2011; White et al., 2007). Even though this gene was thought to be 
differently controlled in patient cells, as RA is delivered to this catabolic enzyme 
via CRABP1, the stages in which we observed simultaneously high levels of 
CRABP1 and low levels CYP26A1 were distinct, questioning CYP26A1 as a 
possible direct way to counter-balance differences in CRABP1 levels.  
Retinol Binding Protein 1 (RBP1), presented higher levels of mRNA in patient 
lines (Day 22 of differentiation), as well as Retinol Dehydrogenase 10 (RDH10) 
(hiPSCs) and Stimulated by Retinoic Acid 6 (STRA6) (from Day 0 to Day 11 of 
differentiation) (Figure 23). All these proteins are indirectly involved in up-
regulation of intracellular levels of RA precursors. 
RBP1 is an important carrier of retinol and retinaldehyde that participates in the 
enzymatic conversions of retinol into retinaldehyde or retinyl esters and 
retinaldehyde into RA (Napoli, 2012). Intriguingly, likewise CRABP1, RBP1 is also 
described to have a retinoid-mediated anti-proliferative activity, this time by 
inhibiting the PI3K/Akt survival pathway (Doldo et al., 2014; Farias et al., 2005a; 
Farias et al., 2005b). 
In the RA biosynthesis, RDH enzymes convert retinol into retinal by oxidation, 
which in turn is further oxidized into RA by RALDH (ALDH) family members. The 
ubiquitous expression of RDH (Duester et al., 2003) led to the interpretation that 
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the controlling point of RA synthesis would be just in the second step of oxidation 
from retinal to RA. Nevertheless, the finding of craniofacial malformation 
phenotype for mice RDH10 mutant (Sandell et al., 2007) clarified the topic, 
showing the importance of this step in RA control for normal embryogenesis. Like 
RBP1, overexpression of RDH10 has been linked to anti-proliferative effects 
(Rossi et al., 2007). 
STRA6 is a membrane receptor with classical described function in mediating 
cellular retinol uptake by binding to a serum retinol binding protein (RBP4), and, 
similarly to RDH10 and RBP1, its silencing is increasing proliferation (Skazik et 
al., 2014) and its expression is associated to apoptosis (Carrera et al., 2013; 
Pavone et al., 2016) 
To conclude, all three RA-related genes that were up-regulated in patient-derived 
cells in different stages of neuronal differentiation (Figure 23), including CRABP1 
(non-canonical role), present anti-proliferative, apoptotic tendency common cell 
response.  
On the contrary, Lecithin retinol acyltransferase (LRAT) that are producing the 
storage form of RA (retinyl esters), showed decreased levels of expression in 
patient cells, particularly at Day 11 of neuronal differentiation (Figure 23) and its 
overexpression is correlated with regulation of cell cycle and malignancy (Hassel 
et al., 2013; Shirakami et al., 2012). 
5.2. eIF2S3 and other translation-related molecules 
5.2.1. Fragile X mental retardation 1 
As mentioned in the introductory section (1.2.2), both Fragile X syndrome, caused 
by silencing of FMR1, and Prader-Willi syndrome, produced by CYFIP1 deletion, 
possess characteristics that very much resemble those found on MEHMO 
patients.  
Due to this similarity in disease phenotype and the fact that FMR1, together with 
CYFIP1 present a relevant role in specific neuronal translation control, inhibiting 
the classic cap-binding translation of special FMR1 target mRNAs (Figure 4), we 
imagined that it would be interesting to check levels of FMR1 and CYIFP1 along 
early neuronal differentiation. Curiously, hiPSCs and EB´s patients exhibited a 
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slightly higher expression levels of FMR1, but from neuronal epithelium-like stage 
on, this pattern reversed and a small significance was observed for this time point. 
Although not significant, the patient group also showed reduced expression for 
CYFIP1, which was consistent along the whole differentiation (Figure 22). The 
confirmation of a down-regulation of FMR1 would open new avenues for 
investigation of possible common affected pathways in MEHMO and these other 
syndromes. 
5.2.2. Protein Phosphatase 1 Regulatory Subunit 15B  
Protein Phosphatase 1 Regulatory Subunit 15B (PPP1R15B) is part of a 
phosphatase complex functioning on eIF2S1 dephosphorylation, thus activating 
protein synthesis. Curiously, PPP1R15B mutation leads to a syndromic 
intellectual disability very similar to MEHMO, suggesting that increase in the
phosphorylated status of eIF2S1 is associated with MEHMO pathomechanism or 
that, alternatively, a shared downstream effect is responsible by the common 
phenotype (Abdulkarim et al., 2015; Harding et al., 2009; Kernohan et al., 2015). 
Supporting this idea, increase in phospho-eIF2S1 by RAX (eIF2S1 kinase 
regulator) knock-out also causes symptoms related to MEHMO syndrome, such 
as reduced body size and anterior pituitary hypoplasia (Dickerman et al., 2015). 
Conversely, decreased phospho-eIF2S1 availability has been linked to problems 
with glucose homeostasis (Harding et al., 2001; Julier and Nicolino, 2010; 
Scheuner et al., 2001; Scheuner et al., 2005). However, PPP1R15B mutation 
(Abdulkarim et al., 2015) also causes diabetes, meaning that both increase as 
decrease of phospho-eIF2S1 might result in the development of this particular 
pancreas-related symptom. In line with this observation, the MEHMO patient 
considered in this study is insulin dependent and presented hypoglycemia in its 
first six months of life, suggesting that the common PPP1R15B and eIF2S3 
downstream deregulated translation rates might affect islets of Langerhans 
hormones production. 
Being lower levels of functional ternary complexes an important effect of eIF2S1 
phosphorylation, the increased PPP1R15B expression observed in MEHMO 
patient iPSCs and Day 11 of neuronal differentiation (Figure 22) might be seen 
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as an attempt to equilibrate ternary complexes formation and therefore 
translation, by decreasing phospho-eIF2S1 levels. 
To conclude, another syndromes (see section 1.2.2) (Armistead et al., 2015; 
Brooks et al., 2014; Favaro et al., 2014; Wang et al., 2013a) which are indirectly 
affecting translation rates also present MEHMO characteristics, such as slow 
growth, microcephaly and craniofacial anomalies. 
5.2.3. Activating Transcription Factor 4  
Even if MEHMO patient cells do not present higher levels of phospho-eIF2S1, 
primary cause of Activating Transcription Factor 4 (ATF4) translation, it is 
reasonable to imagine that EIF2S3 mutation could cause a reduction in ternary 
complexes, hence delayed ribosomal reinitiation, favoring ATF4 translation 
(Vattem and Wek, 2004). Although we could not see any significant difference in
ATF4 protein levels, it was possible to detect higher levels of its mRNA along 
neuronal differentiation, with some significance at Days 0 and 22 (Figure 22). 
ATF4 is a relevant transcription factor, known to be synthetized under different 
stress circumstances, and up-regulated in both mRNA and protein levels to 
circumvent cellular stress (Dey et al., 2010; Dey et al., 2012). Induction of ATF4 
and CHOP (or DDIT3) by ER-stress in MEF cells increased protein synthesis, 
leading to the production of reactive oxygen species that trigger apoptosis (Han 
et al., 2013).  
Interestingly, two eIF2S1 dephosphorylating factors, PPP1R15A and PPP1R15B, 
seems to be targets of both ATF4 and CHOP, but contrarily to PPP1R15A, which 
was up-regulated upon ER stress, PPP1R15B did not show differential 
expression (Han et al., 2013; Novoa et al., 2001). In fact, PPP1R15B factor 
exhibited significant increased mRNA levels in patient iPSCs and Day 11 of 
neuronal differentiation, while PPP1R15A, a significant increase at Day 5 of 
differentiation (Figure 22). Mutation on PPP1R15B, as mentioned previously, 
causes a syndrome very similar to MEHMO. And its overexpression definitely 
contribute to an increase in protein synthesis. 
Other genes likewise regulated by ATF4 and CHOP are RBP4 and RDH10, 
retinoic acid related genes that, when increased, raise retinoic acid precursors 
cell internalization and synthesis, suggesting a possible RA role in the interface 
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translation/apoptosis. It is worth remembering that RDH10 was one of the RA-
related genes analyzed and that it presented increased levels of expression also 
at hiPSCs stage (Figure 23). 
5.2.4. Mechanistic Target Of Rapamycin  
Functioning as part of a sensing mechanism, Mechanistic Target Of Rapamycin 
(MTOR) activation is regulated by factors such as nutrients and growth factors 
availability, and plays a central role in intermediating cell 
survival/growth/proliferative response to environmental conditions. These MTOR 
regulatory pathways are therefore adjusting anabolic processes performance 
such as translation to cell energetic nutrient state (Efeyan et al., 2015; Hay and 
Sonenberg, 2004). Besides the aforementioned (section 1.2.2) eIF4E binding 
protein (4E-BP) phosphorylation via MTORC activation, translation is activated
also by MTOR mediated S6 kinase (S6K1) phosphorylation which stimulates a 
range of other translation effectors involved in ribosomal protein synthesis and in 
eIF4F complex mediated cap-dependent initiation (Hara et al., 1998; Ma and 
Blenis, 2009). 
The hypothesized MEHMO patient decrease in global translation might lead to a 
general increase in amino acid availability. Continuously high amino acid content 
may exacerbate MTOR activation and, in line with this idea, we observed elevated 
levels of MTOR mRNA (Figure 12). Furthermore, the absence of uncharged tRNA 
that maintains general control nonderepressible 2 (GCN2) inactivated might 
decrease phospho-eIF2S1 levels in patient. The reducing phospho-eIF2S1 effect 
is probably a MEHMO cell aim, since increase in levels of PPP1R15B expression 
is also observed. Curiously though, ATF4 transcripts are also elevated in patient 
cells. But, as mentioned earlier, despite possible absence of higher levels of 
phospho-eIF2S1, EIF2S3 mutation might reduce active ternary complexes, thus 
favoring ATF4 translation. 
As nutrient deprivation increases APOE mRNA and protein levels, it would not be 
surprising if EIF2S3 mutation could cause, in long term, reduction of amino acid 
abundance, producing APOE overexpression. On the other hand, considering 
that APOE up-regulation is also detected during apoptosis (another process 
inhibiting general translation) (Lasfargues et al., 2012), we cannot exclude the 
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possibility that changes in gene expression/mRNA translation are not a direct 
consequence of nutrient deprivation, but rather an indirect result of poor 
translation rates due to EIF2S3 mutation (Quinn et al., 2004). 
Finally, as discussed in the introductory section (1.2.2), along with ERK, MTOR 
pathway activation has a function on synapsis plasticity with repercussions on 
memory and learning capacities (Bhakar et al., 2012) and its imbalanced 
stimulation is correlated to neurodevelopmental and neuropsychiatric disorders 
(Costa-Mattioli and Monteggia, 2013). Thus, although no significant differences 
are seen in the course of our neuronal differentiation (Figure 22), a difference in 
mature neurons is not excluded. 
5.3. H2A Histone Family Member X 
Up-regulated in MEHMO patient iPSCs (Table 18), the H2A Histone Family
Member X (H2AFX or H2AX) is a histone protein phosphorylated (γH2AX) upon 
DNA damage, to recruit repair complexes (Paull et al., 2000; Rogakou et al., 
1998). Although H2AX phosphorylation is happening during DNA damage 
response processes, some evidence have indicated that γH2AX is dispensable 
during initial recruiting repair factors, but it is probably important in holding DNA 
ends and factors together (Celeste et al., 2003; Yin et al., 2009). The absence of 
H2AX produced growth retarded mice with decreased mitosis and increased 
chromosomal aberrations (Celeste et al., 2002).  
Although we could observe significant increase in patient H2AX protein levels, it 
is important to mention that it was not possible to apply cell cycle synchronization 
during SILAC experiment and, to minimize problems due to differences arising 
from distinct cell cycle stage, three different time points in two independent 
experiments were analyzed and their results were highly comparable. 
Furthermore, unlike core histones, variant H2AX presents steady levels across 
cell cycles phases (Bretherick et al., 2014). 
It is also noteworthy that the analyzed iPSCs are reprogrammed somatic cells 
that similarly to zygote, also pass through a massive epigenetic reprogramming, 
in which many histones are modified to achieve a completely different 
transcription profile, characteristic of pluripotent cells (Huang et al., 2015). 
Although the exact mechanisms governing epigenetic features are still unknown, 
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it is accepted that iPSCs possess an epigenetic profile very similar to hESCs 
(Guenther et al., 2010; Mallon et al., 2014), but it is also recognized that the so 
called “epigenetic memory” can give rise to differences among iPSC lines, due to 
inheritance of epigenetic markers of the somatic cell of origin (Kim et al., 2010). 
As all iPSCs (control and patient) were generated from keratinocytes, we could 
exclude effects caused by different origin of somatic cells, however individual 
differences could be something revealed in the different iPSC lines.  
Regardless from H2AX canonical role in responding to DNA damage, H2AX 
phosphorylation was described to be highly enriched during embryogenesis, and 
interestingly, also in neurogenic brain areas, such as the subventricular zone 
(Barral et al., 2014; Kafer et al., 2010; Ziegler-Birling et al., 2009). H2AX presence 
on those proliferative tissues is tied to its role in stem cells self-renewal and cell 
proliferative capacity (Andang et al., 2008; Fernando et al., 2011; Turinetto et al., 
2012). Moreover reprogrammed cells having different γH2AX genome distribution 
and pluripotency capacities (assessed via tetraploid assay), presented no 
differences in H2AX protein levels (Wu et al., 2014). Accordingly, despite of any 
difference both patient and control derived iPSCs could have on pluripotency and 
reprogramming efficiency, H2AX protein levels would still remain similar. So, the 
probability of having an iPS cell line with increased H2AX protein levels due to 
varied reprogramming efficiency is minimal, and the observed patient phenotype 
could indeed be a result of EIF2S3 mutation. 
Intriguingly, besides repressing extra-embryonic genes (Wu et al., 2014), thus 
contributing to iPSCs stemness, γH2AX was found to be undirected activated by 
γ-aminobutyric acid (GABA) signaling in both stem cells and neural stem cells 
and negatively regulate their proliferation rates (Andang et al., 2008; Fernando et 
al., 2011). Higher amounts of H2AX does not necessarily mean higher quantities 
of γH2AX. Yet likewise it occurs for serum starvation and chemical induced 
integrative stress response that activates phosphorylation of H2AX (Lu et al., 
2008; Sayers et al., 2013), MEHMO decrease in global translation levels could 
imply higher levels of γH2AX; ergo, restriction of neural stem cells proliferation.  
Finally, it is interesting to consider the possible role that changes in translation 
could have in modulating apoptosis by H2AX phosphorylation, since among a 
variety of other cellular stress triggers, serum starvation is increasing H2AX 
  
111 
 
phosphorylation and inducing apoptosis via mitogen-activated protein kinase 
(MAPK) pathway (Lu et al., 2008), showing in this manner a link between H2AX 
and translation mechanisms (see introduction section 1.2.2). 
5.4. Transketolase 
Transketolase (TKT) is a thiamine-dependent enzyme acting in the pentose 
phosphate pathway of the glucose metabolism, contributing to the production of 
ribose-5-phosphate, nucleotides component, and of reduced nicotinamide-
adenine dinucleotide phosphate (NADPH), important in detoxification and 
synthesis of fatty acids and cholesterol.  
While the oxidative branch of the pentose phosphate pathway is highly active in 
cells like hepatocytes and adipocytes, since the requirement for NADPH in fatty 
acids synthesis is increased there, the non-oxidative branch is ensuring
production of ribose-5-phosphate, essential for DNA and RNA synthesis, and it is 
required in all tissues, especially those highly proliferative. Therefore, it is not 
surprising that TKT activity is commonly elevated in tumors (Ricciardelli et al., 
2015). TKT inhibition, in turn, showed cell cycle arrest in tumor cells (Comin-
Anduix et al., 2001; Rais et al., 1999) and caused decrease in hippocampal 
progenitor cells proliferation (Zhao et al., 2014b).  
Besides presenting a decrease in cell proliferation, chemical TKT inhibition 
promoted a reduction in levels of some translation factors, while TKT own 
translation was markedly increased (Wang et al., 2013b). Likewise related to 
translation, phosphatidylinositol 3-kinase (PI3K)/Akt pathway is orchestrating a 
metabolic mechanism in which amino acid cellular content is activating the 
pathway and determining TKT activity, thereby increasing DNA synthesis and cell 
proliferation (Saha et al., 2014).  
Curiously, disagreeing with what is seen in quantitative proteomics (Table 18), 
patient TKT mRNA levels were significant higher in comparison to control (Figure 
12). This result could be seen as a cell attempt to compensate for the lower TKT 
protein levels, for the protein increased degradation rate, or even for an PI3K/Akt 
exacerbated activation, due to increased cellular amino acid content caused by 
the EIF2S3 mutation.  
To conclude, a very recent report correlates different TKT mutations that lead to 
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lack of activity with a syndrome characterized by delay development, short stature 
and heart malformation (Boyle et al., 2016), features also characteristic of 
MEHMO syndrome. 
5.5. Cystathionine-Beta-Synthase 
Cysteine is considered an essential amino acid, as its synthesis requires the 
uptake of another essential amino acid, the methionine, of which it receives the 
sulfur atom. Among several enzymes catalyzing this process, the cystathionine-
beta-synthase (CBS) is condensing serine with homocysteine to synthetize the 
direct cysteine precursor: the cystathionine.  
Cysteine and methionine are the only amino acids containing sulfur, but differently 
from methionine, cysteine is capable of forming disulfide bonds, which play a 
crucial role in protein folding and, as consequence, in establishing correct protein
function. This importance, added to the fact that cysteine is the least abundant 
amino acid, suggest a regulatory role for this amino acid, in which its availability 
determine translation rates. Actually, a cysteine and methionine availability 
sensing mechanism was described to integrate, in yeast, metabolic status with 
translation capacity of the cells (Laxman et al., 2013). Although described in 
yeast, the authors proposed a parallel mechanism in mammals due to the highly 
conserved pathway involved. Furthermore, amino acid availability is known to 
regulate levels of translation via MTOR pathway activation (Hara et al., 1998; 
Wang et al., 1998)  
In line with these reports, CBS silencing reduced cancer cell and neural stem 
cells proliferation (Szabo et al., 2013; Wang et al., 2013c) and cysteine deficiency 
increased ATF4 levels and reduced mTORC1 activation in human hepatoma cells 
(that are not able to synthetize cysteine from methionine) (Yu and Long, 2016). 
Similarly, cysteine supplementation following proteasome inhibition decreased 
CHOP-mediated cell death and rescued translation via decrease of phospho-
eIF2S1 levels (Suraweera et al., 2012). Thus, although it is impossible to 
determine at the present moment any causality relation for what is observe in 
MEHMO patient iPSCs (mRNA - Figure 12 and protein level - Table 18), CBS 
decline, as well as increase in ATF4 transcript (Figure 22), seems to be a direct 
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consequence of poor translation, as it is the case for serum/nutrient starvation in 
human and yeast cells (Maclean et al., 2002).  
Likewise iPSCs, patient neuronal epithelium-like cells derived from differentiation 
also exhibited lower CBS gene expression in relation to control group (Figure 21). 
Indicating its importance in the CNS development, CBS is particularly highly 
expressed in early neural tube and primary brain vesicles (Quere et al., 1999) 
and its inhibition showed suppression of neural stem cells proliferation and 
differentiation. These proliferative and differentiation effects could be induced by 
cysteine supplementation (Wang et al., 2013c). Lastly, defective CBS activity with 
homocysteine accumulation and cysteine deficiency is related to cognitive 
impairment, seizures and white matter lesions (Barbaux et al., 2000; Kluijtmans 
et al., 1996; Sasai et al., 2015; Suri et al., 2014; Yap et al., 2001). Therefore, 
considering amino acids homeostasis effects in protein synthesis, it would be 
important to assess whether patient CBS lower protein levels effectively reduce 
cysteine synthesis and perhaps more important, if this is a developed patient 
feature and whether its possible effects can be reversed via pyridoxine (vitamin 
B6) treatment, a cofactor required for CBS activity.  
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Closing remarks 
MEHMO is long described as an X-linked intellectual disability syndrome 
(DeLozier-Blanchet et al., 1999). Exome sequencing in a patient diagnosed with 
MEHMO syndrome allowed to conclude that the mutation responsible for the 
observed symptoms is located in the EIF2S3 gene (G.Borck, personal 
communication). Eukaryotic translation initiation factors are known for their ability 
to orchestrate very fine mechanisms of translation control. Among these factors, 
eIF2S3 is an essential subunit of the heteromeric eIF2 factor that binds to GTP, 
enabling tRNA delivery.  
Generation of patient-derived iPSCs and global protein analysis provided 
evidences for the imbalance in translation of some interesting candidates. Gene 
expression analysis confirmed their differential expression, reinforcing a possible 
relevance for disease pathophysiology. Literature research also indicated the 
differentially expressed genes association, by direct and indirect means, with a 
process clearly affected in patients: neurogenesis. 
Certainly it is impossible to exclude the hypothesis that EIF2S3 mutations 
produce a gain of function phenotype, however the fact that women carrying the 
mutation, although presenting out of range occipital measurements, do not 
present any other major symptom indicate that patient’s phenotype (Borck et al., 
2012) might be related to absence of entirely functional protein and lower levels 
of working ternary complexes rather than due to a gain of function problem. 
Furthermore, mutations in different protein sites produce the same syndrome, 
called MEHMO. On the basis of the results presented here, we propose a 
response mechanism (Figure 30) that differently regulates genes specifically 
acting on apoptotic and survival/proliferative pathways, in order to restore the 
disrupted cellular homeostasis created by translation impairment. 
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Figure 30. Proposed hypothesis for differential protein translation of specific genes in 
MEHMO patients. EIF2S3 mutation would drive impaired translation and subsequently 
cellular stress activating response mechanisms to re-establish cellular homeostasis, via 
modulation of survival/apoptotic pathways. Whether patient presents an exaggerated 
activation of either survival/proliferation or apoptosis pathways has to be further evaluated. 
Altogether, this study is a preliminary view of what EIF2S3 disruption is causing 
and, undoubtedly, the use of other patient lines together with the generation of 
isogenic controls by using genetic targeting techniques, such as CRISPR/Cas9 
system (Dow, 2015) will be necessary to validate the data found here. These 
invaluable controls would help to exclude any influences that genetic background 
could have on the changes observed in patient lines and could even elucidate if 
APOE polymorphism is indeed a source of phenotypic variability among patients. 
Moreover, as another possible control line, patient cells could be repaired for 
EIF2S3 mutation. In order to confirm data produced here and explore other 
aspects of the disease, use of other differentiation protocols replicating, for 
example, stages of specific neuronal type and adipocytes development will be 
obviously advantageous. 
Our intention here was to provide an overview about which genes, especially 
which proteins were differently expressed, giving a little contribution towards 
revealing possible altered pathways. Subsequent studies, more deeply 
investigating facts such as the presented increasing levels of APOE upon EIF2S3 
knock-down, might generate insights about the role of each candidate protein and 
their altered expression implications on MEHMO pathophysiology. Ultimately, 
further experiments such as synaptogenesis evaluation and electrophysiology will 
hopefully provide the yet uncovered eIF2 function in nervous system 
development, and in other regulatory pathways, so far not described. 
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Prerequisites for carrying out the project  
Control and patient plucked hair samples are/were requisite for the generation of 
iPS cell lines, and their use had to be approved by the institutional ethics 
committee (Eberhard Karls Universität Tübingen). All participants or their legally 
authorized representatives provided us with written informed consent for use of 
collected biological material. Since somatic cells reprogramming make use of 
mouse and rat embryonic fibroblasts, approval of the ethics committee was also 
needed for work with animals cells. 
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Appendix A 
 
Figure A) Neuronal undirected differentiation. Representative light microscopy images of 
stages from Days 0, 2, 10 and 16. Immunostaining for TUBB3 are seen for neurons from 
Day43 of differentiation.  
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Appendix B 
Table B) Experimental design of SILAC proteome analysis. 
 
First experiment samples 
Medium labelled Time of 
incubation 
Light Medium Heavy 
a K5    6h 
b MH1C3    6h 
 
c 
K5     
6h 
MH1C3    
 
d 
K5     
16h 
MH1C3    
 
e 
K5     
24h 
MH1C3    
 
f 
K5     
6h 
MH1C3    
 
g 
K5     
16h 
MH1C3    
 
h 
K5     
24h 
 MH1C3    
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Second experiment samples 
Medium labelled Time of 
incubation 
Light Medium Heavy 
a K5    6h 
b MH1C1    6h 
c K5     
6h 
MH1C1    
d K5     
16h 
MH1C1    
e K5     
24h 
MH1C1    
f K5     
6h 
MH1C1    
g K5     
16h 
MH1C1    
h K5     
24h 
MH1C1    
 
